RATIONAL DESIGN AND SYNTHESIS OF CHEMICAL PROBES FOR O-GLCNACASE AND OGT

by

Julia E. Heinonen
Bachelor of Arts, Simon Fraser University, 2005

THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF

MASTER OF SCIENCE

In the
Department of Chemistry

© Julia E. Heinonen

SIMON FRASER UNIVERSITY

Summer 2010

All rights reserved. This work may not be reproduced in whole or in part, by photocopy or other means, without permission of the author.
APPROVAL

Name: Julia Heinonen
Degree: Master of Science
Title of Thesis: Rational Design and Synthesis of Chemical Probes for O-GlcNAcase and OGT

Examining Committee:
  Chair: Dr. Paul Li  
  Associate Professor, Department of Chemistry

  Dr. David Vocadlo
  Senior Supervisor
  Associate Professor, Department of Chemistry

  Dr. Robert Britton
  Supervisor
  Assistant Professor, Department of Chemistry

  Dr. Gary Leach
  Supervisor,
  Associate Professor, Department of Chemistry

  Dr. Robert Young
  Internal Examiner
  Professor, Department Chemistry

Date Defended/Approved: July 21, 2010
Declaration of Partial Copyright Licence

The author, whose copyright is declared on the title page of this work, has granted to Simon Fraser University the right to lend this thesis, project or extended essay to users of the Simon Fraser University Library, and to make partial or single copies only for such users or in response to a request from the library of any other university, or other educational institution, on its own behalf or for one of its users.

The author has further granted permission to Simon Fraser University to keep or make a digital copy for use in its circulating collection (currently available to the public at the “Institutional Repository” link of the SFU Library website <www.lib.sfu.ca> at: <http://ir.lib.sfu.ca/handle/1892/112>) and, without changing the content, to translate the thesis/project or extended essays, if technically possible, to any medium or format for the purpose of preservation of the digital work.

The author has further agreed that permission for multiple copying of this work for scholarly purposes may be granted by either the author or the Dean of Graduate Studies.

It is understood that copying or publication of this work for financial gain shall not be allowed without the author’s written permission.

Permission for public performance, or limited permission for private scholarly use, of any multimedia materials forming part of this work, may have been granted by the author. This information may be found on the separately catalogued multimedia material and in the signed Partial Copyright Licence.

While licensing SFU to permit the above uses, the author retains copyright in the thesis, project or extended essays, including the right to change the work for subsequent purposes, including editing and publishing the work in whole or in part, and licensing other parties, as the author may desire.

The original Partial Copyright Licence attesting to these terms, and signed by this author, may be found in the original bound copy of this work, retained in the Simon Fraser University Archive.

Simon Fraser University Library
Burnaby, BC, Canada
ABSTRACT

The attachment of GlcNAc via a β-O-linkage to serine or threonine residues of various nucleocytoplasmic proteins is a common posttranslational modification in multicellular eukaryotes. A glycosyl transferase, UDP-N-acetyl-D-glucosamine: polypeptide-N-acetylglucosaminyl transferase (OGT) acts to install O-GlcNAc while a β-N-acetylglucosaminidase, O-GlcNAcase, removes this modification from proteins. A dynamic relationship between O-GlcNAc and phosphorylation has been proposed and is implicated in cellular signalling and disorders such as Alzheimer disease. In this thesis, the facile syntheses of two series of inhibitors of O-GlcNAcase are described. The potency of these compounds toward O-GlcNAcase is also detailed. Several of these compounds are highly potent and selective inhibitors of O-GlcNAcase. Additionally, 2-acetamido-2-deoxy-5-thio-D-glucopyranosose was synthesized as an analogue of GlcNAc. This compound was used for cell studies and to synthesize para-methoxyphenyl 2-acetamido-2-deoxy-5-thio-D-glucopyranoside as a potential substrate for O-GlcNAcase. Together, these compounds should serve as useful chemical probes to study the function of O-GlcNAc in cells and in vivo.
For my great grandmother Rice, grandma Heinonen and parents, with love.
ACKNOWLEDGEMENTS

I would first like to express my gratitude to my colleagues, who have been by my side, and helped me every step of the way through this journey. Their willingness to collaborate and solve problems as a team has been exceptional. I would especially like to thank Dr. Tong Li, Dr. Ramesh Kaul and Jenny Ji for their thoughtful input to my synthetic projects. Their experience and good humour made the tough spots a lot easier to overcome. During kinetic experiments, I received direction and thoughtful advice from Dr. Matthew Macauley, Garrett Whitworth and David Shen, and I thank them for their patience and helpful input in learning various kinetic techniques. I was fortunate to collaborate with several talented biochemists whom were able to take the synthetic tools that I made and bring them to life through their applications in cell and in vivo studies: thank you to Scott Yuzwa and Xioyang Shen for their hard work using Thiamet-G and to Dr. Tracey Gloster, Wesley Zandberg and David Shen for their work with 5SGlcNAc and pMP-5SGlcNAc. I would especially like to thank Dr. David Vocadlo for the incredible research opportunities he has provided me with, and both his support and criticism throughout my research, which has ultimately helped shape me into a more detailed, mature scientist.

Finally, I would like to thank my fantastic family and friends for their encouragement and love every step of the way. I especially thank my parents and Bryan for encouraging me through the most challenging moments. Your support and love mean the world to me.
TABLE OF CONTENTS

Approval ........................................................................................................................... ii
Abstract ........................................................................................................................... iii
Dedication ....................................................................................................................... iv
Acknowledgements ....................................................................................................... v
Table of Contents ......................................................................................................... vi
List of Figures ................................................................................................................ ix
List of Schemes .............................................................................................................. xi
List of Abbreviations ................................................................................................... xii

Chapter 1: O-GlcNAc, O-GlcNAcase, O-GlcNAc transferase, and their roles in science and medicine ............................................................... 1
  1.1 O-GlcNAc, a simple sugar modification, can be reciprocal to phosphorylation ................................................................. 1
  1.2 The addition and removal of sugar modifications: the fine work of glycosyl transferase and glycoside hydrolase enzymes ............ 5
    1.2.1 Glycoside Hydrolases ................................................................................................................................. 5
    1.2.2 Inhibitors of Glycoside Hydrolases ............................................................................................................ 12
    1.2.3 Glycosyl Transferases .............................................................................................................................. 16
    1.2.4 Inhibitors of Glycosyl Transferases ......................................................................................................... 21
  1.3 O-GlcNAcase, the enzyme of central significance to the following studies ...................................................................................... 27
  1.4 The O-GlcNAc modification and its possible role in the development and progression of Alzheimer disease ......................... 28
  1.5 Aims and goals: Research relating to O-GlcNAcase and the O-GlcNAc modification .............................................................. 31

Chapter 2: Synthesis and testing of inhibitors of O-GlcNAcase .................. 33
  2.1 Rational inhibitor design: basic principles ......................................................................................................................... 33
  2.2 Rational design of inhibitors for O-GlcNAcase ...................................................................................................................... 35
  2.3 The history leading to the development of NButGT ................................................................................................................. 36
  2.4 Design of new thiazoline analogue inhibitors of O-GlcNAcase ......................................................................................... 41
  Results and Discussion ................................................................................................. 44
  2.5 Synthesis of Second Generation Inhibitors of O-GlcNAcase: An Overview of Synthetic Methods ............................................. 44
  2.6 Discussion of synthetic methods ........................................................................................................................................ 46
  2.7 Ki values for synthesized inhibitors .................................................................................................................................. 48
  2.8 Thiamet-G shows promise as a selective in vivo inhibitor and is a possible lead for Alzheimer disease treatment .................... 51
2.9 Methods .................................................................................................... 54
  2.9.1 Preparation of amides (2a-e) from compound (1) .................................. 54
  2.9.2 Preparation of per-O-acetylated thiazoline analogues (3a-e) from (2a-e). ................................................................. 55
  2.9.3 Preparation of deprotected thiazolines 4a-e. ....................................... 56
2.10 Aminothiazoline series: synthetic methods ............................................. 56
  2.10.1 Preparation of isothiocyanate 5 from amine 1 .................................. 56
  2.10.2 Preparation of thioureas 6a-g ......................................................... 57
  2.10.3 Preparation of the per-acetylated 2'-aminothiazoline derivatives 7a-g ................................................................. 58
  2.10.4 Preparation of deprotected 2'-aminothiazoline analogues 8a-g ...... 58
2.11 Synthesized second generation inhibitors for O-GlcNAcase: NMR and elemental data ................................................................. 61
2.12 Kinetic analysis of potent inhibitors using 4-methylumbelliferyl 2-acetamido-2-deoxy-β-D-glucopyranoside as a substrate .............. 76
2.13 Kinetic analysis of moderate to poor inhibitors using 4-nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside (pNP-GlcNAc) as a substrate .......................................................................................... 76

Chapter 3: Synthesis of 2-acetamido-2-deoxy-5-thio-α-D-glucopyranose (5SGlcNAc) and derivatives ......................................................... 78
  3.1 Synthesis of 2-acetamido-2-deoxy-5-thio-α-D-glucopyranose (5SGlcNAc). ..................................................................................... 78
  3.1.1 Rationale behind the synthesis of 5SGlcNAc ..................................... 78
  3.2 Results and Discussion: synthetic challenges and triumphs .............. 79
    3.2.1 Synthesis of 5SGlcNAc (18) ............................................................. 79
    3.2.2 5SGlcNAc: a possible metabolic inhibitor of the glycosyl transferase, OGT ................................................................. 82
  3.3 Synthesis of para-methoxyphenyl 2-acetamido-2-deoxy-5-thio-β-D-glucopyranoside (pMP-5SGlcNAc): making a new sub-strate for O-GlcNAcase ................................................................. 84
    3.3.1 Synthesis of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-gluco-pyranosyl chloride: a putative glycosyl donor for glycosylation reactions ................................................................. 84
    3.3.2 Synthesis of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranosyl trichloroacetimidate (22) ..................................... 85
  3.4 Synthesis of a potential substrate for O-GlcNAcase ................................ 86
    3.4.1 Glycosylation of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α- D-glucopyranosyl trichloroacetimidate (22) with para-methoxyphenol under low temperature conditions ................................................................. 86
    3.4.2 Back to the drawing board: an α-glycosylated product will not be useful, O-GlcNAcase only processes β-glycosides. ......................... 87
    3.4.3 The synthesis of para-methoxyphenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-β-D-glucopyranoside ........................................ 88
    3.4.4 pMP- 5SGlcNAc (26): isolated! ........................................................... 90
  3.5 pMP-5SGlcNAc (26): a substrate for O-GlcNAcase ................................ 91
  3.6 Methods .................................................................................................... 92
LIST OF FIGURES

Figure 1.1 The structural differences between glucose and GlcNAc. ........................... 1
Figure 1.2 Amino acid acceptors for GlcNAc. ............................................................... 2
Figure 1.3 UDP-GlcNAc donor substrate of OGT. ........................................................ 3
Figure 1.4 The dynamic relationship of O-GlcNAcylation and phosphorylation on proteins is mediated by several enzymes. .............................................. 4
Figure 1.5 Inverting mechanism for a glycoside hydrolase. ........................................... 7
Figure 1.6 The retaining mechanism for glycoside hydrolases involving an enzymic nucleophile. ................................................................................... 10
Figure 1.7 The retaining mechanism for glycoside hydrolases involving anchimeric assistance. ............................................................................... 11
Figure 1.8 Covalent inhibition contrasted with non-covalent inhibition of glycoside hydrolase enzymes. ...................................................................... 12
Figure 1.9 Structure of Nojirimycin and derivatives. ..................................................... 15
Figure 1.10 Stereochemical outcomes for glycosyl transferase reactions. .................... 17
Figure 1.11 Inverting mechanism of glycosyl transferases. ........................................... 18
Figure 1.12 Proposed retaining mechanism for glycosyl transferases. ......................... 20
Figure 1.13 Examples of some moderately successful glycosyl transferase inhibitors. ........................................................................................................... 23
Figure 1.14 Common components involved in a glycosyl transferase transition state. ........................................................................................................... 24
Figure 1.15 Binding interactions between UDP and OGT ............................................. 26
Figure 1.16 Increasing O-GlcNAc modification and decreasing phosphorylation on cellular proteins may be accomplished using an O-GlcNAcase inhibitor. ........................................................................................................... 30
Figure 2.1 Structure of NBuTG. .................................................................................. 35
Figure 2.2 Structures of PUGNAc and streptozotocin. ............................................... 36
Figure 2.3 Three fluoro-analogues of GlcNAc and their predicted rates of processing by O-GlcNAcase. ........................................................................... 38
Figure 2.4 Structure of NAG-thiazoline (left) contrasted with the structure of the oxazoline intermediate (right). ................................................................. 39
Figure 2.5 Data showing the inhibition of O-GlcNAcase by thiazoline analogues synthesized by Whitworth et al. and their selectivity for O-GlcNAcase over β-hexosaminidase (pH 6.5). ................................. 41
Figure 2.6  Interactions between NButGT (left) with key residues of BtGH84 O-GlcNAcase contrasted with allosamizoline with plant chitinase (right). ................................................................. 43

Figure 2.7  Twelve inhibitors synthesized and their respective $K_i$ values for inhibition of O-GlcNAcase. ................................................................. 49

Figure 2.8  Interactions between Thiamet-G with key residues of BtGH84 O-GlcNAcase.  53

Figure 2.9  Summary of synthetic methods and yields for twelve inhibitors of O-GlcNAcase. ................................................................. 60

Figure 3.1  Structures of GlcNAc and 5S-GlcNAc. ................................................................. 79

Figure 3.2  UDP-5S-GlcNAc. ................................................................. 83
LIST OF SCHEMES

Scheme 2.1 Overview of the synthesis of (4a-e)............................................................45
Scheme 2.2 Overview of methods for the synthesis of 8a-g.................................45
Scheme 3.1 Synthesis of Ac-5SGlcNAc (17) and 5SGlcNAc (18).........................80
Scheme 3.2 Attempts at glycosylating 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-
thio-α-D-glucopyranosyl chloride. ........................................................................85
Scheme 3.3 Synthesis of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-
glucopyranosyl trichloroacetimidate glycosyl donor (22). ..................................86
Scheme 3.4 An α-glycoside product is generated under low temperature reaction
conditions..................................................................................................................87
Scheme 3.5 An increase in reaction temperature increased the ratio of β- to α-
glucosides..................................................................................................................89
Scheme 3.6 Deprotection of pMP-5SGlcNAc 23 and 24 glycosylated products.........90
LIST OF ABBREVIATIONS

General terms

calcd. calculated
eq. equivalents
expts. experiments
$\delta^+$ partially positive
$\delta^-$ partially negative
h hour(s)
HRMS high resolution mass spectrometry
pH acid dissociation constant
$pK_a$ negative log of the acid ionization constant (Ka)
r.t. room temperature
U.V. ultraviolet

Units of measure

Å Ångstrom(s)
°C degree Celsius
g gram(s)
nm nanometer(s)
nM nanomole per litre
μM micromole per litre
mg milligram(s)
mL millilitre(s)
mM millimole(s) per litre
mmol millimole(s)
mol mole(s)
M molar
m/z mass to charge ratio
MHz megahertz
ppm parts per million
% percentage
General chemistry terms
α alpha
β beta
cat. catalytic
D dextrorotatory
in vacuo under vacuum
L levorotatory
$S_{N1}$ unimolecular nucleophilic substitution reaction
$S_{N2}$ bimolecular nucleophilic substitution reaction
$S_{Ni}$ nucleophilic substitution with internal return
TLC thin layer chromatography

Biological terms
APP amyloid precursor protein
ADP adenosine diphosphate
Asn asparagine
Asp aspartate
ATP adenosine triphosphate
BtGH84 B. thetaoiotaomicron
CAZy Carbohydrate Active Enzymes
dNA deoxyribonucleic acid
GH glycosyl hydrolase
GlcNAc 2-acetamido-2-deoxy-D-glucopyranose
GDP guanidine diphosphate
GTP guanidine triphosphate
HBSP hexosamine biosynthetic pathway
His Histidine
IC$_{50}$ 50% maximal inhibitory concentration
in vitro in glass
in vivo in life
$K_{cat}$ catalytic rate constant (turnover number)
$K_D$ dissociation constant
$K_i$ inhibition constant
$K_m$ Michaelis constant
Leu leucine
Lys lysine
O-GlcNAc 2-acetamido-2-deoxy-D-glucopyranose
O-GlcNAcase β-N-acetylglicosaminidase
OGT UDP-N-acetyl-D-glucosamine:polypeptide-N-acetylglicosaminyl transferase
PHF paired helical filaments
PC-12 phenochromocytoma cells
Pro proline
PTM post translational modification
RNA ribonucleic acid
UDP uridine diphosphate
V rate
V_{max} maximum rate

Chemical Terms
CaCO₃ calcium bicarbonate
CDCl₃ deuterated chloroform
CO₂ carbon dioxide
CF₃COOH trifluoroacetic acid
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCM dichloromethane
DCC dicyclohexylcarbodiimide
DMF dimethylformamide
EDC N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide
Et₃N triethylamine
HCl hydrochloric acid
H₂O dihydrogen monoxide
K₂CO₃ potassium carbonate
MgSO₄ magnesium sulphate
NAG-thiazoline 1,2-deoxy-2'-methyl-α-D-glucopyranoso-[2,1-δ]-Δ2'-thiazoline
NaHCO₃ sodium bicarbonate
NaOMe sodium methoxide
NBut-GT 1,2-dideoxy-2'-propyl-α-D-gluco-pyranoso[2,1-δ]-Δ2'-thiazoline
p para
PUG-Nac O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate
5-SglcNAc 2-acetamido-2-deoxy-5-thio-α-D-glucopyranose
SnCl₄ tin (IV) chloride
THF  tetrahydrofuran
Thiamet-G  1,2-dideoxy-2'-aminoethyl-α-D-glucopyranoso[2,1-δ]-Δ2'-thiazoline

**Techniques and related terms**

$^{13}$C-NMR  carbon nuclear magnetic resonance
$^1$H-NMR  proton nuclear magnetic resonance
d  doublet
dd  doublet of doublets
E.A.  elemental analysis
HRMS  High Resolution Mass Spectrometry
$J$  coupling constant
m  multiplet
NMR  Nuclear Magnetic Resonance
ppm  parts per million
s  singlet
t  triplet
TLC  thin layer chromatography
$\delta$  chemical shift
Chapter 1: O-GlcNAc, O-GlcNAcase, O-GlcNAc transferase, and their roles in science and medicine.

1.1 O-GlcNAc, a simple sugar modification, can be reciprocal to phosphorylation.

2-acetamido-2-deoxy-D-glucopyranose (GlcNAc) is an aminosugar, differing from glucose by replacement of the 2-hydroxyl group with a 2-acetamido group (Figure 1.1). Glucose is the biosynthetic precursor to GlcNAc.\(^1\) However, the roles that GlcNAc play in eukaryotic cells are varied and differ significantly from those played by glucose.\(^2\)\(^-\)\(^7\)

![Figure 1.1 The structural differences between glucose and GlcNAc.](image)

One role that GlcNAc plays is to modify intracellular proteins.\(^7\)\(^-\)\(^9\) A protein that has GlcNAc attached to the hydroxyl group of a serine or threonine residue is referred to as an O-GlcNAc modified protein. The anomeric configuration of the GlcNAc residue O-glycosidically linked in this way is exclusively β, and to date, the addition of other sugars to O-GlcNAc to make longer chains has not been described. Because it is only after the protein has been synthesized within the
cell that O-GlcNAc is added, this modification is a post-translational modification (PTM).\textsuperscript{9,10} O-GlcNAc was first discovered over twenty years ago by Torres and Hart.\textsuperscript{9}

Figure 1.2 Amino acid acceptors for GlcNAc. Above are shown the amino acids, threonine and serine. When found within certain proteins, serine or threonine residues can act as acceptors for the O-GlcNAc modification. Beside these two amino acids is illustrated an O-GlcNAc modified protein (note the $\beta$-glycosidic linkage).

It is important to appreciate that the O-GlcNAc modification is a reversible PTM. Indeed, the O-GlcNAc modification is dynamic, where the addition and removal of the sugar may occur several times during the lifetime of a protein.\textsuperscript{11,12} This dynamism suggests that O-GlcNAc plays a role in signalling pathways similar to the well established signalling pathways mediated by phosphorylation.\textsuperscript{10,13} The ability of O-GlcNAc to be added and subsequently cleaved off proteins in a cyclical manner arises from the action of two key enzymes; UDP-$N$-acetyl-$D$-glucosamine:polypeptide-$N$-acetylglucosaminyl transferase (OGT)\textsuperscript{14,15} and $\beta$-$N$-acetylglucosaminidase (O-GlcNAcase).\textsuperscript{16,17} OGT uses uridine 5’ diphospho-$N$-acetyl-$D$-glucosamine (UDP-GlcNAc, Fig. 1.3) as a glycosyl donor to transfer GlcNAc residues to the threonine and serine residues of target protein acceptors\textsuperscript{14,18} (Fig. 1.4). UDP-GlcNAc is biosynthesized within eukaryotic cells from glucose through a series of steps that form what is referred to as the
hexosamine biosynthetic pathway (HBSP). In contrast, O-GlcNAcase, is responsible for cleavage of O-GlcNAc off of modified proteins, thereby returning the proteins to their unmodified states (Figure 1.4).\textsuperscript{16,17}

![Figure 1.3 UDP-GlcNAc donor substrate of OGT.](image)

\textbf{Figure 1.3} \textit{UDP-GlcNAc donor substrate of OGT.} UDP-GlcNAc is the donor substrate used by the glycosyl transferase OGT. This enzyme is responsible for transferring GlcNAc onto proteins. The nucleotide diphosphate, highlighted in red, is a good leaving group making the glycosyl transfer kinetically feasible and thermodynamically favourable.

Interestingly, it has been shown in a small number of cases that residues that can be O-GlcNAc modified can also sometimes be phosphorylated through the action of a class of enzymes known as kinases.\textsuperscript{19} Kinases are well known to transfer phosphate groups from donors such as adenosine triphosphate (ATP) or adenosine diphosphate (ADP) to a variety of biological substrates, including serine and threonine residues.\textsuperscript{19} A group of enzymes known as phosphatases can function to remove phosphate moieties from such phosphorylated proteins.\textsuperscript{20} This reciprocal dynamic relationship is illustrated in Figure 1.4:
Figure 1.4 The dynamic relationship of O-GlcNAcylation and phosphorylation on proteins is mediated by several enzymes.

OGT is the enzyme responsible for transferring GlcNAc from UDP-GlcNAc onto various protein acceptors to β-O-GlcNAc. Conversely, O-GlcNAcase is responsible for the cleavage of the glycosidic bond of O-GlcNAc, consequently liberating the hydroxyl group of the protein and releasing GlcNAc. Free hydroxyl groups can in some cases be competitively modified either by OGT or by a kinase. Kinases phosphorylate these residues using ATP donors as a source of the phosphoryl group. A phosphatase can return the phosphorylated protein site to an unmodified state.

The fact that phosphorylation seems to sometimes occur at the same or adjacent sites\textsuperscript{21} to where the O-GlcNAc modification can be found suggests that O-GlcNAc, in collaboration with phosphorylation, may play a role in regulating cellular processes as a dynamic team. Much research remains to be done in order to understand the roles played by O-GlcNAc in the working of cells. However, the O-GlcNAc modification appears critically important and has been found to be essential for embryonic stem cell viability.\textsuperscript{22}

The O-GlcNAc modification has also been implicated in several different disease states within humans. Research has suggested that the O-GlcNAc modification may play a role in the development of diabetes,\textsuperscript{23,24} Alzheimer disease,\textsuperscript{25-27} cardiovascular disease,\textsuperscript{28-30} and cancer.\textsuperscript{31,32} It also seems to play a
role in immune system function. In light of these proposed roles played by O-GlcNAc in several disease states, it is clear that research performed to gain greater understanding of this dynamic modification, as well as its regulation, could have significant implications in both basic research and medical applications.

1.2 The addition and removal of sugar modifications: the fine work of glycosyl transferase and glycoside hydrolase enzymes.

Proper processing of the O-GlcNAc modification depends upon the action of OGT and O-GlcNAcase. OGT is an enzyme that is a part of the superfamily of enzymes known as the glycosyl transferases, enzymes that transfer sugars to a variety of biological substrates. In contrast, O-GlcNAcase is part of the large superfamily of glycoside hydrolases, which are responsible for the cleavage of glycosidic bonds found in various glycoconjugates. A general understanding of these two classes of enzymes will be useful for the discussion within this thesis. An overview of the catalytic mechanisms of these two classes of enzymes is therefore provided below.

1.2.1 Glycoside Hydrolases

Glycoside hydrolases (GH) are enzymes that are responsible for the cleavage of glycosidic bonds of sugars linked to other sugars, lipids, or proteins. Glycosidic bonds are remarkably stable and it has been estimated that the half life for spontaneous hydrolysis of a single glycosidic bond is approximately 5 million years! Glycoside hydrolases can increase the rate of glycosidic bond cleavage by up to \(10^{17}\) times, making glycoside hydrolases one
of the most proficient superfamilies of enzymes.37 Because of the wide range of glycan structures that exist in nature, there is also a wide range of glycoside hydrolases that process these structures. Due to the large number and diversity of the glycoside hydrolases found within the glycoside hydrolase superfamily, they have been subdivided into various families according to their amino acid sequence and structural similarities. This well established classification system, CAZy (Carbohydrate Active Enzymes, http://www.cazy.org), is a highly useful and widely referenced classification system.38 Glycoside hydrolases that are found in the same family often act on the same sugars and almost always use highly similar mechanisms. Generally speaking there are two possible ways that glycoside hydrolases act on substrates, and this partly defines their catalytic mechanism: the stereochemistry of the product can be either retained or inverted relative to that of the substrate.35

Inversion of stereochemistry at the anomeric center involves one chemical step in which a molecule of water acts as a nucleophile to displace the leaving group.35 The nucleophilicity of the water molecule is enhanced by a general base catalytic residue and departure of the leaving group is aided by a general acid catalytic residue (Figure 1.5). Both these residues have been found most commonly to be enzymic carboxyl groups.35
Figure 1.5 Inverting mechanism for a glycoside hydrolase.

An inverting catalytic mechanism is thought to proceed via a concerted one step process through a dissociative transition state. General acid catalysis from an enzymic carboxylic acid aids departure of the leaving group, while a second carboxylate residue acts as a general base and enhances the nucleophilicity of a water molecule.

With this general scenario in mind for an inverting mechanism, inversion of stereochemistry at the anomeric center may proceed along either an $S_N1$, or an $S_N2$ reaction coordinate. Classically speaking, with $S_N1$ reactions, the stereochemistry of the product can either be inverted or retained with respect to the stereochemistry of the starting material. This is the case because, during an $S_N1$ reaction a discrete cation is formed,

and the nucleophile can attack either face of this planar carbocation. These geometrically different processes lead to a mixture of retained and inverted stereochemistry in the resulting products.

An enzymatic $S_N1$ reaction, however, can result in exclusively inverted products since the face of the carbocation that would lead to a retained product may be blocked by the leaving group, which may diffuse out of the enzyme active site relatively slowly. Although there is no experimental evidence for an $S_N1$ reaction
occurring for any inverting glycoside hydrolases, the scenario certainly remains possible. In contrast, for an $S_N2$ mechanism, the incoming nucleophile attacks the anomeric center at the same time that the leaving group departs. The geometric requirements of the reaction ensure that such a process always leads to an inverted product.$^{39}$

Two different, yet related, catalytic mechanisms are used by glycoside hydrolases that use a retaining mechanism. The first mechanism is a two step process where, in the first step of the reaction, a general acid catalyst facilitates departure of a leaving group while another residue acts as a nucleophile to displace the leaving group and stabilize an enzyme sequestered intermediate, which is most likely a covalent glycosyl enzyme intermediate. The second step of this mechanism is essentially the reverse of the first step; a general base catalyst facilitates the attack of a molecule of water at the anomeric center, intercepting the enzyme sequestered intermediate and forming a hemiacetal product having retained stereochemistry at the anomeric center relative to that of the substrate.$^{35}$ Both residues are generally enzymic carboxylates although exceptions are known.$^{35}$ Because it is generally believed that for retaining glycoside hydrolases the intermediate is a covalent glycosyl-enzyme intermediate, this type of mechanism is often referred to as a double displacement mechanism$^{35}$ (Figure 1.6). The second retaining mechanism involves the nucleophilic participation of the N-acetyl group found at position two of the pyranose ring of naturally occurring hexosamines such as GlcNAc.$^{35,40}$ In this scenario, a general acid catalytic residue aids departure of the leaving group. Attack of the nucleophilic N-
acetyl group is aided by a second residue in the active site that orients and polarizes this N-acetyl group, most likely by acting as a general base. The net result is the formation of an enzyme sequestered oxazoline intermediate (Figure 1.7). This intermediate is then broken down by the general base catalyzed attack of water at the anomeric center, as well as a general acid catalyzed opening of the oxazoline ring. The stereochemical constraints of the reaction ensure that the process occurs only with retention of configuration at the anomeric center. This mechanism is known as a substrate-assisted catalytic mechanism or an anchimeric assistance mechanism. There are some rare mechanistic exceptions for retaining glycoside hydrolases but these will not be discussed here and the reader is advised to see a recent review for a discussion of these alternatives.
Figure 1.6 The retaining mechanism for glycoside hydrolases involving an enzymic nucleophile.
Two carboxyl groups play key catalytic roles in retaining glycoside hydrolases. One acts as a general acid to facilitate departure of the leaving group from the anomic center. A second carboxyl group residue acts as a catalytic nucleophile to attack the anomic center. A covalent enzyme intermediate is likely formed and is then broken down in a second step that is the near reverse of the first step.
Figure 1.7 The retaining mechanism for glycoside hydrolases involving anchimeric assistance.
The anchimeric assistance mechanism involves two key catalytic carboxyl groups. One acts as a general acid to aid departure of the leaving group while a second group acts to polarize the $N$-acetyl group to act as a nucleophile. Attack of the $N$-acetyl group of the anomeric center displaces the leaving group and results in the formation of an oxazoline intermediate. The second step is the near reverse of the first step and produces the hemiacetal product having the same anomeric configuration as the substrate.
1.2.2 Inhibitors of Glycoside Hydrolases

Inhibitors of glycoside hydrolases can be subdivided into two broad classes; those that bind covalently to their target enzyme and those that bind non-covalently.\textsuperscript{42} Covalent inhibitors associate with the target enzyme and then react to form a covalent bond between the inhibitor and the enzyme.\textsuperscript{43,44} Typically, a nucleophilic residue within the active site of the enzyme reacts with an electrophillic moiety present on the inhibitor. The formation of this covalent adduct leads to loss of activity because the inhibitor physically blocks access of the substrate to the active site and also because the inhibitor often modifies an active site residue that is critical for catalytic action (Figure 1.8).\textsuperscript{42} In contrast to such inactivators, a non-covalent inhibitor associates with the target enzyme through non-covalent interactions such as van der Waals, hydrogen bonding, and ionic interactions. Inhibition by these molecules is reversible (Figure 1.8).\textsuperscript{42}

![Figure 1.8 Covalent inhibition contrasted with non-covalent inhibition of glycoside hydrolase enzymes.](image)

A) The mechanism of inactivation of a retaining β-glucosidase by conduritol β-epoxide. Note how the aspartate residue in the active site acts as a nucleophile to open the epoxide, forming a covalent bond to the inhibitor, leading to inactivation of the enzyme. B) In contrast, one can see the types of interactions between a non-covalent inhibitor streptazotocin with BtGH84, a bacterial homologue of O-GlcNAcase.\textsuperscript{45}
Covalent inhibitors are useful for several purposes, the most common of which is to identify active site residues. Labeled active site residues can be identified by X-ray crystallography or mass spectrometry. The identified residues can then be altered by site-directed mutagenesis and kinetic analysis of the mutant enzymes can be used to confirm whether or not the identified residue has an essential catalytic function or simply serves a structural role. In addition, highly specific covalent inactivators can be used to selectively inactivate a target enzyme in cells to observe the effect of eliminating the enzyme activity within cells.

The inhibitors that will be discussed in this thesis are those that associate with O-GlcNAcase through non-covalent means. Non-covalent inhibitors are preferred as potential therapeutics and as research tools since there is less likelihood these molecules will adventitiously inactivate unrelated enzymes. Notably, many good non-covalent inhibitors are inspired to some extent by the proposed transition state structure stabilized by the enzyme being targeted. The transition state is a fleeting species wherein bonds are breaking and forming in a concerted manner. In the 1940’s, Pauling proposed that inhibitors with the highest affinity for an enzyme are those possessing a structure resembling that of a “strained activated complex” (now termed a transition state). The transition states for glycoside hydrolases are generally thought to possess oxocarbenium ion character. This arises from the transition state having only partial bonds formed with the attacking nucleophile and the leaving group as well as delocalization of the lone pair of electrons of the endocyclic oxygen. In these
dissociative transition states the anomeric carbon is believed to possess trigonal character (sp$^2$ hybridization) at both the endocyclic oxygen and anomeric carbon.$^{35,49}$ This double bond character in the pyranose ring means that there is some distortion from the ground state conformation of the substrate to a more planar and energetically unfavourable half chair or boat conformation.$^{35,49,50}$ Such transition state conformations, are something to consider when designing inhibitors of glycoside hydrolases. An additional point to consider when designing glycoside hydrolase inhibitors is the build up of partial positive charge on the endocyclic oxygen and anomeric pyranose at the transition state.

The first rational approach to inhibitor design is to replicate to some extent the charge distribution in the transition state, most often by using a piperidine derivative having a nitrogen atom at the position usually occupied by O-5 or C-1 of the pyranose ring. Such piperidine rings are protonated at physiological pH and are believed to mimic the transition state.$^{51}$ An example of such an inhibitor is Nojirimycin, which is the first natural product found to inhibit a glycoside hydrolase. This compound was isolated from a strain of *Streptomyces* in 1966 and was found to possess antibiotic properties.$^{52}$ Nojirimycin was also found to be capable of inhibiting both $\alpha$- and $\beta$-glucosidases.$^{53}$ From this scaffold several derivatives were created, including deoxynojirimycin and deoxygalactonojirimycin, which were found to inhibit $\alpha$- and $\beta$-mannosidases and galactosidases, respectively (Figure 1.9).$^{44}$
Figure 1.9 Structure of Nojirimycin and derivatives.
The structures of Nojirimycin, deoxynojirimycin and deoxygalactonojirimycin are shown from left to right respectively. Each is a well known inhibitor of different α- and β-glycosidases. The inhibitory potency of these compounds is due to the amino group within the ring at the position normally occupied by the endocyclic oxygen.

A second rational approach to creating a successful inhibitor for glycoside hydrolases is to engineer the molecule to adopt a shape resembling that of the transition state used by the enzyme of interest. This approach can be an effective way to enhance binding to enzymes that have specific binding pockets where key catalytic groups are strategically positioned. If the inhibitor is oriented within the active site in a way that allows it to interact with key catalytic residues in a manner similar to how a transition state structure might bind, then it is likely the inhibitor will capture some transition state binding energy and bind fairly well. Examples of inhibitors that mimic the geometry of the transition state are glucolactones and gluconolactans and these are often good inhibitors, though they lack any charge.

Of course, not all inhibitors of glycoside hydrolases are transition state mimics. There are plenty of examples of inhibitors that bind successfully simply by having a structure that can position itself and interact favourably in the active site through serendipitous hydrogen bonds, van der Waals interactions, and electrostatic interactions. Indeed, there are examples of glycosidase inhibitors that do not have any features of carbohydrates. Some examples of such
inhibitors include proteins\textsuperscript{56,57}, cyclopeptides\textsuperscript{58}, and relatively simple amines\textsuperscript{59}. Reflecting on this last point, it is important to maintain an open mind when designing inhibitors of glycoside hydrolases and avoid becoming hindered by trying to approach the problem from only one angle.

1.2.3 Glycosyl Transferases

All glycosyl transferases catalyze glycosidic bond formation using sugar donors that contain a substituted phosphate leaving group.\textsuperscript{60} Activated donor sugars are most often nucleoside diphosphate sugars such as UDP-GlcNAc (Figure 1.3) or guanidine diphosphate (GDP) mannose. In other cases, however, nucleoside monophosphate sugars or lipid phosphate sugars are glycosyl donors. The structures that accept the transferred glycosyl unit are called acceptors and are most commonly other sugars, but can also be proteins, lipids, nucleic acids, or other small molecules.\textsuperscript{60} Generally speaking, the glycosyl unit is transferred onto the nucleophillic oxygen of the hydroxyl substituent of the acceptor, but transfer can also occur to other atoms, such as nitrogen, sulphur and carbon.\textsuperscript{60} With these basics in mind, a topic of interest regarding the glycosyl transferases is their mechanism of action. There are two possible stereochemical outcomes of the reactions catalyzed by this class of enzymes; the product can either be retained or inverted with respect to the stereochemistry of the donor sugar (Figure 1.10).\textsuperscript{60} As with glycoside hydrolases, glycosyltransferases have been divided into many families based on amino acid sequence similarities. The classification system CAZy (Carbohydrate Active Enzymes, http://www.cazy.org) is a useful resource for those interested in glycosyl transferases.\textsuperscript{38}
Figure 1.10 Stereochemical outcomes for glycosyl transferase reactions. The two possible stereochemical outcomes for a glycosyl transferase catalyzed glycosyl transfer from a nucleotide diphosphate sugar onto a hydroxyl group of an acceptor sugar. The acceptor can also be a protein, lipid, or nucleic acid.

Each glycosyl transferase is stereospecific and catalyzes its reaction using only one of the stereochemical outcomes. The catalytic mechanism of inverting glycosyl transferases involves a single displacement of the phosphate leaving group through what is generally believed to be a dissociative SN2 reaction mechanism. An active site residue of the enzyme serves as a general base to aid the attack of the incoming nucleophile (the acceptor) and displacement of the activated phosphate leaving group (Figure 1.11). It has been found that inverting glycosyl transferases with bound acceptors often show conserved residues such as carboxylates or imidazoles that are within hydrogen bonding distance of the nucleophilic hydroxyl group undergoing reaction, consistent with their roles as general base catalysts. In further support of this proposed mechanism, it has
been found that site directed mutagenesis of an active site carboxyl residue of an inverting glycosyl transferase from the GT2 family of enzymes, known as ExoM, resulted in complete loss of catalytic activity.\textsuperscript{62} Also, a histidine residue has been unambiguously shown to be the general base in the sialyltransferase \textit{Campylobacter jejuni} alpha-2,3/2,8-sialyltransferase (CstII) from the glycosyltransferase family 42.\textsuperscript{61} Some glycosyl transferases use a divalent metal ion, such as Mn\textsuperscript{2+} or Mg\textsuperscript{2+}, to aid departure of the nucleotide diphosphate. Those that do not use a positively charged metal ion often have positively charged amino acid residues, within the active site to fulfil this role.\textsuperscript{60}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{glycosyl-transferase.png}
\caption{Inverting mechanism of glycosyl transferases.}
\end{figure}

Inverting glycosyl transferases are generally believed to use a direct-displacement \textit{SN}2 reaction mechanism that results in inverted configuration at the anomeric center. The glycosyl transferase shown here is a metal ion dependant enzyme.

For retaining glycosyl transferases, two catalytic mechanisms have been proposed. One of these is a double-displacement mechanism involving a covalently bound glycosyl enzyme intermediate in which the sugar residue is attached to an appropriately positioned nucleophile within the active site. The
reason why this mechanism is described as a ‘proposed’ mechanism is that mechanistic characterization of glycosyl transferases is quite challenging (Figure 1.12). There has not yet been any concrete evidence that a covalently linked intermediate does exist, although there have been numerous studies seeking to provide scientific support for this hypothesis. Perhaps the issue in supporting this potential mechanism is finding the appropriate techniques to trap the putative intermediate. Only further studies will provide a clear understanding.
A second proposed catalytic mechanism that leads to exclusive retention of stereochemistry in retaining glycosyl transferases is a non-concerted process. This proposed mechanism is a special type of $S_{N1}$ reaction, known as $S_{Ni}$, and occurs when a discrete ion pair intermediate forms. This mechanism is termed $S_{Ni}$ because the ‘$i$’ denotes the internal return of a nucleophile to the same face.
from which the leaving group departed. This mechanism was first described to account for the products observed to arise from the decomposition alkyl chlorosulphites.\textsuperscript{60,63} The unique features that account for the retention of stereochemistry in the case of alkyl chlorosulphites are that the leaving group undergoes decomposition, leading to the production of a nucleophile that is held as an ion pair on the same face as the leaving group. Decomposition of the leaving group species and attack of the newly formed nucleophile occurs at a rate that exceeds any other attack on the electrophile. Many authors now propose this type of S\textsubscript{N}1 mechanism for glycosyl transferases that lead to retention of stereochemistry.\textsuperscript{60} In the case of glycosyl transferases, the acceptor is positioned adjacent to the leaving group such that it can only attack the same face of the glycosyl cation intermediate from which the leaving group departed.

The take home message for the glycosyl transferases is that they function to attach sugars to different substrate acceptors within the cell, yet their precise mechanisms of action remain to be clarified. The main glycosyl transferase that will be discussed in this thesis is OGT, which is an inverting glycosyl transferase.

1.2.4 Inhibitors of Glycosyl Transferases

The development of potent and selective inhibitors of glycosyl transferases is still in its infancy.\textsuperscript{64,65} This is partly due to many unknowns regarding the mechanistic details of how glycosyl transferases function. However, the importance of the development of inhibitors for this class of enzymes is well recognized.\textsuperscript{64,66-68} In addition to their potential as valuable scientific tools that should aid in the study of glycobiology, selective inhibitors of
glycosyl transferases have potential applications as therapeutics for diseases that are linked to carbohydrate-protein interactions.\textsuperscript{64} Despite this potential, and the considerable effort that has been put into developing inhibitors for members of this class of enzymes, most compounds have been found to be quite poor and only a minority have been found to be potent.\textsuperscript{65} Of these potent glycosyl transferase inhibitors, only a handful can engage their targets in cells.\textsuperscript{32,69-73}

Despite the challenges of generating inhibitors for glycosyl transferases, a few general observations have been collected over the last twenty years. Some carbohydrate-based inhibitors that have seen success in inhibiting glycosyl transferases are those that contain nitrogen in the place of the endocyclic oxygen of the carbohydrate ring or at the position of the anomeric center. This may be partly due to the fact that the ring nitrogen of these inhibitors is basic and is protonated under physiological conditions (pH 7.4).\textsuperscript{44,51,54} The resulting cationic species can interact with anionic groups within the active site of glycosyl transferases. Some noteworthy examples of amino-based sugar inhibitors for glycosyl transferases include some of the structures illustrated in Figure 1.13.\textsuperscript{74-76}
Figure 1.13 Examples of some moderately successful glycosyl transferase inhibitors.

The above structures are examples of glycosyl transferase inhibitors that possess significant binding to different glycosyl transferases. From left to right, these inhibitors target mammalian α-1,3-fucosyltransferase,\textsuperscript{74} ceramide glucosyltransferase,\textsuperscript{75} α-1,3-galactosyltransferase,\textsuperscript{76} β-1,4-galactosyltransferase,\textsuperscript{77} and an α-2,6-Sialyltransferase,\textsuperscript{78} respectively.

It is obvious that the binding affinities of the inhibitors illustrated in figure 1.13 are modest and though all inhibit their targets fairly well \textit{in vitro}, none have been shown to act in cells. Each has a basic nitrogen atom, which likely aids in binding to their targets for reasons discussed earlier. Despite the observation that an appropriately positioned nitrogen atom seems to be helpful for successful inhibition of glycosyl transferases there is clearly room for improvement. In terms of developing inhibitors that may act as therapeutics, they need to be able to permeate through cellular membranes in order to act \textit{in vivo}; something that has only been accomplished for glycosyl transferase inhibitors in a very limited number of cases.\textsuperscript{32,69,70,72,73} Challenges in developing inhibitors of glycosyl
transferases also arise from the intrinsic features of the glycosyl transferases themselves. For example, the transition state for glycosyl transferases is complex and often involves four distinct structures; the sugar donor, the sugar/protein acceptor, a metal cation, as well as the enzyme itself.\textsuperscript{60,79} These groups all play a role in the transition state, making it difficult to emulate with a simple small-molecule inhibitor (Figure 1.14).

Figure 1.14 Common components involved in a glycosyl transferase transition state. The transition state of glycosyl transferases is complex. It often involves four distinct groups.
One reason it is useful to have an understanding of the transition state structures used by glycosyl transferases is that transition state structures are generally thought to interact very tightly with the enzyme. As was discussed in detail in section 1.2.2 about glycoside hydrolases, the preferential tight binding of the transition state is believed to confer much of the catalytic power of enzymes. As a result of this tight binding, proposed transition state structures are often used as inspiration for inhibitor design. However, it is evident that with glycosyl transferases, emulating the transition state structure is difficult. Further, binding of acceptor substrates and nucleosides to glycosyl transferases tends to be relatively weak; these species often bind to glycosyl transferases with $K_D$ values in the mM range. As a consequence, generating substrate or bisubstrate analogues that inhibit these enzymes can also be difficult. It is known, however, that glycosyl transferases, including OGT, bind UDP and UDP-GlcNAc quite tightly with $K_D$ values often in the low micromolar range. Therefore, understanding the binding of glycosyl donor substrates and UDP is worthwhile. The pyrophosphate moiety of the sugar-nucleoside diphosphate donors has been well documented as being important in binding, especially since the anionic charges makes this portion of the sugar able to form favourable ionic interactions with cationic groups within the active site. These areas of positive charge in the active site of glycosyl transferases may present themselves in the form of one or more positively charged amino acid residues, as seen in Figure 1.15 for OGT. Alternatively the cationic group may be a divalent metal cation, often $\text{Mn}^{2+}$. In light of this, maintaining the pyrophosphate bridge of the donor sugar
may prove beneficial for inhibitor binding. Alternatively, incorporating moieties that mimic the charge or characteristics of the diphosphate group may also be a productive approach to generating good inhibitors of glycosyl transferases.

![Figure 1.15 Binding interactions between UDP and OGT.](image)

In red are shown the amino acid residues from a bacterial homologue of OGT and how they interact with the UDP portion of the nucleotide sugar donor. Various hydrogen bonding and ionic interactions form between this portion of the donor and the enzyme active site. This suggests the importance of incorporating this phosphate bridge, or a polar mimic of this group, when designing inhibitors of OGT and other glycosyl transferases.  

Clearly, there is a long way to go in terms of generating potent inhibitors of glycosyl transferases that can be used in tissues. It might be beneficial if much of the current research efforts regarding glycosyl transferases focused on gaining a better understanding of the mechanisms of these enzymes, since this knowledge could make design of good inhibitors more feasible.
1.3 **O-GlcNAcase, the enzyme of central significance to the following studies**

A more detailed discussion of O-GlcNAcase will be of importance to define the purposes of the research presented in this thesis. Although the focus of this thesis is on the synthetic processes used to make various small molecule targets, each final compound was synthesized to test the function of O-GlcNAcase or OGT. One of the reasons O-GlcNAcase is of interest to the glycoscience community is that it has been proposed to play key regulatory roles within mammals.\(^{83-87}\) Some fundamental research over the past two decades supports this claim: the O-GlcNAc modification is present on a wide range of proteins and it is found on RNA polymerase, which may have implications on protein expression. Changes in O-GlcNAc levels have also been proposed to alter the behaviour of specific proteins by modulating protein-protein interactions,\(^{85,86,88}\) DNA binding,\(^{89}\) and enzyme activity.\(^{87,90,91}\) Interestingly, in some cases the proteins that are O-GlcNAc modified have also been found to be phosphorylated, at the exact same or adjacent sites as O-GlcNAc can be found.\(^{92-94}\) Because phosphorylation has long been known to play regulatory roles within cells, it has been postulated that O-GlcNAc also plays a role in these processes since it has the capacity to block phosphorylation at some sites.\(^{94}\) This relationship between O-GlcNAc and phosphorylation is mediated in part by O-GlcNAcase since this enzyme is responsible for the removal of O-GlcNAc.

Consistent with its proposed involvement in various cellular processes, O-GlcNAc has been suggested to have roles in some disease states, although such proposals require further scientific studies to gain compelling support. For
example, it has been shown that increased O-GlcNAc levels correlate with insulin resistance and it has therefore been suggested that increased O-GlcNAc induces with the development of type 2 diabetes.\textsuperscript{23,24} However, it remains unclear if increased O-GlcNAc levels cause diabetes.\textsuperscript{95} It is important to maintain clear distinctions between research pointing to correlative observations and research that provide clear causative links. To date, O-GlcNAc levels have been correlated with several disease states but there is limited evidence supporting a causative link. In light of these observations, it is evident that investigating the dynamic levels of O-GlcNAc in cells is worthwhile. Specific tools to investigate the roles of O-GlcNAc within the cellular environment are likely to be useful in making these new discoveries.

One useful tool to aid the study of O-GlcNAc would be the development of highly selective and potent inhibitors of O-GlcNAcase. Using appropriate inhibitors, we can study the repercussions of increased O-GlcNAc levels in cells \textit{in vivo}. This ability may help us to gain greater insight as to which processes or disease states are dependant on increased O-GlcNAc in the cell, and this in turn may point to potential areas where further research be directed. A major aim of this thesis is to develop an inhibitor that can permeate into cells, is potent, and is selective for O-GlcNAcase.

\textbf{1.4 The O-GlcNAc modification and its possible role in the development and progression of Alzheimer disease.}

Alzheimer disease is a neurological disorder characterized by two primary pathological features.\textsuperscript{25} The first of these are the β-amyloid plaques, which are
abnormal aggregates of a peptide derived from proteolytic processing of the amyloid precursor protein (APP). β-amyloid plaques are found in the interneuronal tissue of diseased individuals. The second diagnostic pathology found in Alzheimer disease are neurofibrillary tangles, which are abnormal aggregates of the microtubule associated protein tau, occurring within neurons. Tau normally functions to stabilize microtubules within cells, however, cells that accumulate neurofibrillary tangles die.

One of the key features of tau present in neurofibrillary tangles is that it is abnormally hyperphosphorylated. As much as 4-fold greater levels of phosphorylation are seen on tau in the brains of Alzheimer patients compared to phosphorylation levels found on tau from brain tissue of individuals who had suffered no neurodegeneration. This hyperphosphorylation of tau is generally thought to be the factor leading to its aggregation into paired helical filaments (PHF), which are the species that spontaneously assemble to form neurofibrillary tangles. Interestingly, tau has been shown to be O-GlcNAc modified and a reciprocal relationship between O-GlcNAc and phosphorylation has been proposed for tau. The dynamic balance between phosphorylation and O-GlcNAcylation points to some very interesting possibilities as to how one might be able to alter this balance using chemical tools. Since there is a connection between tau being present in a hyperphosphorylated state and its aggregation into pathological tangles, then perhaps by decreasing tau phosphorylation we may be able to decrease the rate of formation of neurofibrillary tangles. One way in which this might be achieved is by inhibition of O-GlcNAcase. By blocking the
action of O-GlcNAcase, we could increase O-GlcNAc on tau and this might prevent tau hyperphosphorylation and the formation of neurofibrillary tangles (Figure 1.16).

Figure 1.16 Increasing O-GlcNAc modification and decreasing phosphorylation on cellular proteins may be accomplished using an O-GlcNAcase inhibitor. Blocking the action of O-GlcNAcase with a selective and potent inhibitor that is also cell permeable, would increase the levels of O-GlcNAc modification of proteins in vivo. Because several of the sites that are O-GlcNAc modified appear to be reciprocally phosphorylated, increasing the levels of O-GlcNAc modification could decrease levels of phosphorylation. This may be an effective method to block hyperphosphorylation of tau in vivo, thereby providing a potential therapeutic approach for preventing neurofibrillary tangles.

We aimed to test some hypotheses discussed above by first designing an inhibitor that is cell permeable, selective, potent, and able to enter into the brain in vivo. The role that I played in this endeavour was to synthesize several compounds that could be used to investigate these ideas. This was ultimately achieved by creating a panel of rationally designed inhibitors based on previous studies carried out by our group on the catalytic mechanism of O-GlcNAcase. The process of inhibitor design and the principles used will be discussed in detail in Chapter 2 of this thesis.
1.5 Aims and goals: Research relating to *O*-GlcNAcase and the *O*-GlcNAc modification.

In light of the information presented thus far, it is evident that there is reason for enthusiasm for research relating to the *O*-GlcNAc modification. On a personal note, when I began research in the Vocadlo laboratory I was extremely interested in contributing to this pool of growing knowledge, specifically in uncovering the potential role of *O*-GlcNAc in Alzheimer disease. It is evident, however, both from experience as a graduate student as well as from the vast body of research reported, that both directed research, with the aims of accomplishing specific goals, balanced with an open and mindful curiosity to what one might find along the way, is conducive to successful science. In keeping with this line of thinking some interesting and unexpected results were met. The details of each aim that will be discussed in each chapter are outlined here:

1) **Synthesis of inhibitors of O-GlcNAcase** – Chapter 2.

2) **Testing of inhibitors of O-GlcNAcase** – Chapter 2.

3) **Synthesis of 2-acetamido-2-deoxy-5-thio-β-D-glucopyranose (5SGlcNAc), a structural variant of GlcNAc: a possible inhibitor of OGT (in a UDP-donor form).** - Chapter 3.

4) **Synthesis of glycosides of 2-acetamido-2-deoxy-5-thio-β-D-glucopyranosides as substrates and probes for O-GlcNAcase.** - Chapter 3
It is evident from this summarized list of aims, that our overall interests for this thesis are to; a) create new, rationally designed, highly selective and potent inhibitors of O-GlcNAcase as potential tools for scientific research and to investigate the role of O-GlcNAc in diseases that have been proposed to be involved with the dysfunction of the O-GlcNAc modification and b) to investigate the scope of what kind of substrates might be processed by O-GlcNAcase.
Chapter 2: Synthesis and testing of inhibitors of O-GlcNAcase.

2.1 Rational inhibitor design: basic principles.

The synthesis of enzyme inhibitors that have in vivo efficacy is challenging. Several parameters must be considered when designing such inhibitors including; selectivity for the target enzyme, potency, solubility, pharmacokinetics, and the ability of the compound to cross cellular membranes to reach intracellular targets. Of these parameters, effective binding to the target is of foremost importance and is often optimized early on. When possible, careful analysis of the target’s active site is beneficial in the design of potent inhibitors.\textsuperscript{99-103} It is important that the size, shape, and polarizability of the inhibitor are appropriately matched to the amino acid residues present in the targeted active site.\textsuperscript{104} Harnessing favourable polar, ionic, hydrogen bonding or hydrophobic interactions can greatly increase the strength of binding of an inhibitor.\textsuperscript{51,105,106}

One way to obtain leads to enzyme inhibitors is to consider the properties of the natural substrate.\textsuperscript{107,108} If a substrate can bind well to the active site of its target, then a compound having a similar structure may also bind well. Complicating such an approach to inhibitors, however, is that some enzymes need to alter their conformation to bind their substrate effectively or bind the substrate in a conformation that is uncommon in solution.\textsuperscript{109-112} Furthermore it is known that intermediates and transition state structures found along the reaction
coordinate bind most tightly to the active site. This last point highlights the importance of gaining an understanding of the catalytic mechanism of the target enzyme, including transition state and/or intermediates formed during the catalytic cycle. Since transition state and intermediate structures tend to bind well, trying to emulate these structures is often fruitful for designing potent inhibitors.

A second parameter that is important is inhibitor selectivity. When designing an inhibitor for a target enzyme that might be useful as a research tool it is important to have an understanding of functionally related enzymes. Off target effects arising from either inhibition of functionally related enzymes, or entirely different proteins, can lead to detrimental effects in cells or animal models. An example of this comes from a consideration of the lysosomal β-hexosaminidases, which are functionally related to O-GlcNAcase in that they also cleave terminal β-linked N-acetylglucosamine residues off from glycoconjugates. Inhibition of these two β-hexosaminidases has the potential to lead to serious problems since their dysfunction is known to lead to congenital disorders known as Tay Sachs and Sandhoff’s diseases. In these disorders a series of glycosylated lipids known as gangliosides accumulate within neurons, leading to a host of complications and eventual death.

These two considerations, amongst others including pharmacokinetics, solubility, and cellular permeability are important considerations when designing enzyme inhibitors, and collectively play a role in an approach to creating inhibitors known as “rational design”.

34
2.2 Rational design of inhibitors for O-GlcNAcase.

When designing inhibitors for O-GlcNAcase, key amino acid residues present within the active site were considered. A series of analogues were designed having different substituents, but key structural features were retained in all compounds. These common features were directly inspired by a lead compound synthesized previously, which we were using as a starting point to generate inhibitors with improved potency for O-GlcNAcase and selectivity over the two functionally related lysosomal hexosaminidases, discussed previously in Section 2.1. This lead molecule, 1,2-dideoxy-2'-propyl-α-D-glucopyranosyl[2,1-d]-Δ2'-thiazoline, was synthesized previously by Garrett Whitworth in our laboratory, and is often abbreviated as ‘NButGT’ (Figure 2.1).

NButGT

Figure 2.1 Structure of NButGT.

NButGT has a $K_i$ value of 600 nM ($K_i$ is defined as the inhibitor concentration required to inhibit half of all enzyme activity in solution) and a selectivity of 700-fold for O-GlcNAcase over the functionally related lysosomal β-hexosaminidases. This was an encouraging lead compound, but there was room for improvement. Our approach to improving upon this compound was to
consider which parts of NButGT made it an effective inhibitor and which parts could be altered to improve its potency and selectivity. To gain an appreciation for which parts of NButGT were key to inhibition of O-GlcNAcase, a brief history of the development of NButGT and other O-GlcNAcase inhibitors will be described in the following section.

2.3 The history leading to the development of NButGT.

Historically, the two main compounds used as inhibitors of O-GlcNAcase were 2-deoxy-2(\{methyl(nitroso)amino\}carbonyl)amino)-β-D-glucopyranose (streptozotocin) and O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc) (Figure 2.2).\(^{16,17,120-122}\) These two inhibitors were effective in blocking the action of O-GlcNAcase, however were not ideal for use in cells or \textit{in vivo} due to off-target effects.

\[\text{PUGNAc} \quad \text{Streptozotocin} \]

\[\text{Figure 2.2} \quad \text{Structures of PUGNAc and streptozotocin.}\]

Streptozotocin is able to inhibit O-GlcNAcase, but is not a potent inhibitor of this enzyme \((K_i = 2 \text{ mM})\).\(^{121}\) Additionally, it is observed to have cytotoxic effects in cells\(^{123}\) through alkylation of DNA and the production of radical species.\(^{123,124}\) These cytotoxic effects lead to cell death, and therefore make streptozotocin
inappropriate for cellular experiments to study the effects of O-GlcNAcase inhibition.\textsuperscript{125} PUGNAc is a potent inhibitor of human O-GlcNAcase ($K_i = 52$ nM),\textsuperscript{16} but is also a potent inhibitor of the human lysosomal $\beta$-hexosaminidases ($K_i = 52$ nM).\textsuperscript{40} Because PUGNAc inhibits all of these enzymes, it is not ideal for cellular or \textit{in vivo} experiments to study the effects of selectively inhibiting O-GlcNAcase. Therefore, development of potent and selective inhibitor of O-GlcNAcase was needed, as it would be a valuable research tool to study the dynamics of the O-GlcNAc modification in cells or animal models.

Understanding the mechanism of O-GlcNAcase was expected to be useful for the development of a selective inhibitor. Macauley, Whitworth, and co-workers sought to study its mechanism by conducting several in depth enzyme kinetic studies and then using this information to generate a small library of inhibitors that were cell permeable, potent, and selective for O-GlcNAcase.\textsuperscript{40} As a first step, three alternative catalytic mechanisms were considered for O-GlcNAcase. These included a single step inverting mechanism, a double displacement retaining mechanism, and a double displacement retaining mechanism involving substrate-assisted catalysis (see Figures 1.5, 1.6, 1.7 for an overview of these mechanisms). A key difference between these mechanisms is the involvement of the 2-acetamido group of the substrate; only in the substrate-assisted catalytic mechanism does it play an active role. In order to address the possible involvement of this group, several substrate analogues were synthesized, each bearing differing levels of fluorine substitution on the N-acetyl group. The added fluorine atoms on the N-acetyl group decrease the basicity of the amide oxygen.
Decreasing the nucleophilicity in this way was predicted to decrease the rate of catalysis if O-GlcNAcase does use a substrate-assisted mechanism (Figure 2.3).[^40]

![Chemical Structures](image)

**Figure 2.3** Three fluoro-analogues of GlcNAc and their predicted rates of processing by O-GlcNAcase.
The rates of catalysis were measured as a function of fluorescence generated by the O-GlcNAcase-catalyzed liberation of the 4-methylumbelliferyl leaving group of the substrates.

Though the human lysosomal β-hexosaminidases are in a different CAZy family, and are unrelated to O-GlcNAcase they were already known to use substrate-assisted catalysis.[^40] These compounds were therefore tested with one of these human hexosaminidase enzymes to validate the approach. As predicted, when the number of fluorines was increased, a decrease in second order rate constant was observed with this enzyme. A similar pattern was also seen with O-GlcNAcase. Through this experiment, as well as further kinetic studies, that will not be discussed in detail here, it was concluded that O-GlcNAcase, in common

[^40]: Reference to additional information
with lysosomal β-hexosaminidase, uses a substrate assisted catalytic mechanism.\textsuperscript{40}

A further experiment to test this conclusion was performed. 1,2-deoxy-2'-methyl-α-D-glucopyranoso-[2,1-Δ]2'-thiazoline (NAG-thiazoline) (Figure 2.4) was previously designed to mimic the putative bicyclic oxazoline intermediate (Figure 2.4) formed in the course of the substrate-assisted catalytic mechanism for a plant hexosaminidase. This compound was tested with human O-GlcNAcase with the expectation being that it would inhibit the enzyme.

![Structure of NAG-thiazoline and oxazoline intermediate](image)

**Figure 2.4** Structure of NAG-thiazoline (left) contrasted with the structure of the oxazoline intermediate (right).

It was discovered that this compound was a potent inhibitor of O-GlcNAcase ($K_i = 180$ nM),\textsuperscript{40} binding 21,000 fold more tightly than the parent saccharide. It was hypothesized that this tight binding may be attributed to it mimicking a transition state structure resembling the oxazoline intermediate.\textsuperscript{40} These studies collectively led to the clear conclusion that O-GlcNAcase hydrolyzes O-GlcNAc from proteins using a substrate-assisted catalytic mechanism.
Several observations from these studies, as well as ones involving streptozotocin, led to the development of the first class of selective inhibitors of O-GlcNAcase by Whitworth, Macauley, and coworkers.\textsuperscript{40} One observation was that the structure of a human lysosomal β-hexosaminidase reveals a snug pocket that tightly accommodates the methyl substituent of the acetamido group of GlcNAc.\textsuperscript{126} Additionally, streptozotocin, which has a sterically bulky N-acyl group, shows some weak 10-fold preference for O-GlcNAcase over β-hexosaminidase.\textsuperscript{40,127} It was hypothesized in the Vocadlo group that this bulky group impaired the bonding of streptozotocin to the lysosomal β-hexosaminidase. These observations aided the development of seven inhibitors where the 2'-position of the thiazoline ring was elaborated with alkyl chains of differing lengths, starting with a methyl group and progressing to a hexyl chain (Figure 2.5). It was predicted that the differing chain lengths of these compounds would confer selectivity for O-GlcNAcase over the lysosomal β-hexosaminidases. As predicted, the findings from the studies involving these compounds revealed that increasing the chain length of each compound resulted in a decrease in potency for β-hexosaminidase. An addition of even one methylene unit to the alkyl chain attached to the thiazoline ring resulted in a 460-fold increase in the $K_i$ value of the inhibitor for β-hexosaminidase. Furthermore, it was found that an increase in chain length in the inhibitors was much better tolerated by O-GlcNAcase (Figure 2.5) and these inhibitors were consequently highly selective for O-GlcNAcase over β-hexosaminidase, suggesting that O-GlcNAcase has significant space in the region surrounding the 2-acetamido group of substrates.\textsuperscript{40}
Whitworth, Macauley, and associates made significant achievements in discovering the mechanism for O-GlcNAcase. These mechanistic studies enabled the generation of inhibitors of O-GlcNAcase; some with significant potency and excellent selectivity compared to the previously available inhibitors, PUGNAc and streptozotocin.

![Chemical Structure](image)

<table>
<thead>
<tr>
<th>R group</th>
<th>O-GlcNAcase $K_i$ (μM)</th>
<th>β-hexosaminidase $K_i$ (O-GlcNAcase $K_i$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CH$_3$</td>
<td>0.07</td>
<td>0.070</td>
</tr>
<tr>
<td>CH$_2$CH$_3$</td>
<td>0.12</td>
<td>32</td>
</tr>
<tr>
<td>(CH$_2$)$_2$CH$_3$</td>
<td>0.23</td>
<td>340</td>
</tr>
<tr>
<td>(CH$_2$)$_3$CH$_3$</td>
<td>1.5</td>
<td>4,600</td>
</tr>
<tr>
<td>(CH$_2$)$_4$CH$_3$</td>
<td>57</td>
<td>11,000</td>
</tr>
<tr>
<td>CH(CH$_3$)$_2$</td>
<td>1.6</td>
<td>720</td>
</tr>
<tr>
<td>CH$_2$CH(CH$_3$)$_2$</td>
<td>5.7</td>
<td>4,000</td>
</tr>
</tbody>
</table>

Figure 2.5 Data showing the inhibition of O-GlcNAcase by thiazoline analogues synthesized by Whitworth et al. and their selectivity for O-GlcNAcase over β-hexosaminidase (pH 6.5). It is clear that longer ‘R’ group chain lengths are better tolerated by O-GlcNAcase than the β-hexosaminidases.

2.4 Design of new thiazoline analogue inhibitors of O-GlcNAcase.

It is clear, based on the studies performed by Macauley and Whitworth, that the thiazoline moiety which confers mimicry of the transition state (resembling the putative oxazoline intermediate) is key to the potency of the inhibitors. It was also clear that the selectivity of NButGT for O-GlcNAcase over the functionally related lysosomal β-hexosaminidase enzymes was due to the presence of an alkyl chain attached to the thiazoline ring. Therefore, it was
reasoned that retaining such bulky groups on the 2'-position of the thiazoline ring would be important for retaining selectivity.

We aimed to synthesize analogues that possessed different substituents attached to the 2'-position of the thiazoline ring moiety and investigate the ability of these analogues to inhibit O-GlcNAcase. On the basis of detailed mechanistic studies by Cetinbas and co-workers in the Vocadlo laboratory that revealed key residues in the active site interacting with the substrate, it was predicted that having an electron-donating group, such as an amine directly attached to the thiazoline ring of the new analogues would increase binding affinity. The basis for this hypothesis was that Asp$^{174}$ of human O-GlcNAcase was found to be important in catalysis; it is proposed to interact with the amide group of the substrate, and act as a general base having a pKa of ~5.$^{41,128}$ This low pKa indicated that this carboxyl residue would be negatively charged at physiological pH. The pKa of the thiazoline ring of NButGT itself was also quite low, pKa = 5.5, therefore this inhibitor would not be protonated at physiological pH and no favourable interaction between the endocyclic nitrogen of the inhibitor and enzyme carboxylate would take place.$^{117}$ The proposals regarding the position and function of this residue were later supported by the structure acquired by collaborators Rebecca Dennis and Prof. Gideon Davies at the University of York, (see Figure 2.6 of a bacterial homologue of O-GlcNAcase from B. thetaiotaomicron (BtGH84)).$^{129}$ By generating a 2'-aminothiazoline ring, the pK$_a$ of the endocyclic nitrogen was predicted to increase, in keeping with the aminooxazoline ring of allosamizoline,$^{130}$ making it likely this compound would be
protonated under physiological conditions. It was expected that protonation of this group would introduce a hydrogen bonding or ionic interaction with Asp242 not possible with NButGT, thereby increasing its affinity for O-GlcNAcase. Such an interaction would be reminiscent of the interaction of the basic protonated aminooxazoline ring of allosamizoline observed in complex with a plant chitinase (Figure 2.6).\textsuperscript{130} Selectivity for O-GlcNAcase over the lysosomal β-hexosaminidases could be retained by maintaining an alkyl chain at the 2′-position of the thiazoline ring (Figure 2.6). A variety of different substituents could also be attached to the thiazoline ring. This would provide more information as to what might make an effective inhibitor of O-GlcNAcase by defining the space of O-GlcNAcase’s active site and capturing possible adventitious interactions.

NButGT with key residues

\textit{BtGH84 O-GlcNAcase}\textsuperscript{117}

allosamizoline with plant chitinase\textsuperscript{130}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.6.png}
\caption{Interactions between NButGT (left) with key residues of \textit{BtGH84 O-GlcNAcase} contrasted with allosamizoline with plant chitinase (right).}
\end{figure}
Results and Discussion


The synthesis of the new inhibitors for O-GlcNAcase synthesized here can be divided into two main groups: an aminothiazoline series (those inhibitors that possess a 2'-amino group on the thiazoline ring) and an alkylthiazoline series (those that possess 2'-alkyl, substituted alkyl, or aryl substituents on the thiazoline ring). The synthesis of thiazolines on carbohydrate scaffolds is well established and several literature procedures were helpful in the synthesis of these analogues.40,131-133 There were two general synthetic routes used to make these analogues of NButGT, which are summarized in Schemes 2.1 and 2.2. These compounds were accessed using well established chemistry40,131,134 in either three or four step routes. One route involved the acylation of commercially available amine 1. The second route involved reaction of a well known isothiocyanate intermediate135 with various amines.131,136 The subsequent steps, including the conversion of amides to thioamides134 and cyclization of thioamides and thioureas to thiazolines, have been reported for related carbohydrate scaffolds. The deprotection conditions used are general methods used reliably for carbohydrates.40,134 For more detailed procedures, refer to the methods found in Section 2.9.
**Scheme 2.1 Overview of the synthesis of (4a-e).**

- a) 1 (1 eq.) desired carboxylic acid (1.2 eq.) and EDC or DCC (2.5 eq.) or acid chloride (1.2 eq.). Plus Et$_3$N (2 eq.) in DCM or DMF, r.t.;
- b) 2a-e (1 eq.), Lawesson’s reagent (0.6 eq.), toluene, 80-85°C;
- c) 3a-e, K$_2$CO$_3$ (cat.)
- d) MeOH, r.t.
- e) AcOH, MeOH.

**Scheme 2.2 Overview of methods for the synthesis of 8a-g.**

- e) 1 (1 eq.), thiophosgene (2 eq.), CaCO$_3$ (3 eq.), DCM, H$_2$O, r.t.;
- f) 5 (1 eq.), amine or HCl·amine of the desired ‘R’ substituent (1.2 eq.), Et$_3$N (1.2 eq.), acetonitrile, r.t.;
- g) 6a-g (1 eq.), Lewis acid (either SnCl$_4$ (4 eq.) or trifluoroacetic acid (7.5 eq.)), DCM, r.t.;
- h) 7a-g, K$_2$CO$_3$ (cat.), r.t.
2.6 Discussion of synthetic methods.

Coupling reactions between 1,3,4,6-tetra-O-acetyl-2-amino-2-deoxy-β-D-glucopyranose hydrochloride and various carboxylates were carried out using EDC or DCC to introduce the desired groups and generate various alkyl thiazolines having different 2'-substituents. These coupling reactions were relatively straightforward. The main issue encountered at this step was isolating the desired compounds during the work-up procedure, as most of these compounds were partially soluble in water. Back extracting each aqueous layer with DCM was required to ensure the synthesized compounds were effectively recovered from aqueous layers. Separation of the desired products from excess reagents and minor side products was generally simple, but sometimes separation by flash silica column chromatography was challenging due to poor separations. In such cases more than one chromatography step was needed for complete product recovery.

Generation of thioamide intermediates and subsequent cyclization\textsuperscript{40,134} to form thiazolines 3a-e required, for best yields, that the reactions be kept dry and maintained under an atmosphere of N\textsubscript{2}. Heating the reaction to 80-85°C was imperative to drive the reaction forward and also aided the dissolution of the Lawesson's reagent in the toluene.\textsuperscript{134} It was most common for the thiazoline products to have a higher $R_f$ value than the starting material on TLC (ethyl acetate:hexanes 1:1), but sometimes the differences in polarity were only slight, making purification by silica column chromatography difficult. It was found to be important, to obtain reasonable yields (50% or higher), that the product was
isolated immediately following concentration of the reaction mixture under high vacuum. Yields for formation of thiazolines 3a-e were rarely high and were typically around 50%. This relatively low yield may be due to the number of side products that often formed as judged by TLC analysis.

For the synthesis of 2'-aminothiazoline inhibitors formed from the known isothiocyanate 5 (Scheme 2.2), care was required in handling the highly reactive isothiocyanate. It was important that the coupling reaction to form thioureas 6a-g, was kept dry to avoid the possibility of water reacting with the isothiocyanate. The work up procedure used to obtain thioureas 6a-g generally required back extraction of all aqueous layers to obtain good yields.

For cyclization of thioureas 6a-g to form thiazolines 7a-g, an acid catalyst was dissolved with the compounds in a solution of DCM under an atmosphere of N\textsubscript{2}. When using SnCl\textsubscript{4}, it was imperative that the reaction was dry, since moisture was found to lead to degradation of thiazoline products, most likely due to the formation of HCl. Thiazoline compounds can be sensitive to Brønsted acids, especially in aqueous conditions due to the acid lability of the thiazoline ring. Once the cyclization reaction was complete as judged by TLC analysis (15 h), reactions were treated with a solution of saturated NaHCO\textsubscript{3} until the evolution of CO\textsubscript{2} ceased and the pH of the solution was between 7 and 8. Quenching of SnCl\textsubscript{4} was a crucial step, since when too little saturated NaHCO\textsubscript{3} was added to the crude mixture, degradation of the thiazoline products 7a-g occurred after the work-up procedure. It was later found that using TFA (7.5 eq.) instead of SnCl\textsubscript{4} was advantageous for cyclizing thiourea compounds 6a-g to thiazolines 7a-g.
Using this work up procedure, the product contained less impurities and there was the added advantage of not having to deal with tin waste. The use of TFA was only used in two cyclization procedures, but its future use for creating 2'-aminothiazoline analogues is highly recommended.

The deprotection of analogues **4a-e** and **8a-g** in methanol was completed by addition of a catalytic amount of either K$_2$CO$_3^{107}$ or NaOMe.$^{40,134}$ Both methods worked well, however, one advantage of using K$_2$CO$_3$ (cat.) was that the reaction could simply be filtered and concentrated directly, whereas with NaOMe it was important that the reaction was neutralized with a dilute solution of acetic acid in methanol.$^{134}$ Because these final compounds were sometimes heat sensitive, it was advantageous to concentrate the reactions under high vacuum without heating.

### 2.7 $K_i$ values for synthesized inhibitors.

$K_i$ values for O-GlcNAcase were measured by Dixon plot analysis (see the appendix for details). Either 4-methylumbelliferyl 2-acetamido-2-deoxy-$\beta$-D-glucopyranoside or 4-nitrophenyl 2-acetamido-2-deoxy-$\beta$-D-glucopyranoside was used as a substrate for O-GlcNAcase. Assays were carried out at 37°C at pH 7.4 using fluorescence or absorbance, respectively (see methods section(s) 2.12 and 2.13 for further details).

There were two families of inhibitors synthesized containing different groups attached to the thiazoline ring. It is clear that the potency of these two families against O-GlcNAcase vary greatly (Figure 2.7).
Our prediction that increasing the basicity of the thiazoline ring would improve binding affinity to O-GlcNAcase proved correct. Again, this is likely due to the exocyclic nitrogen donating electron density into the thiazoline ring, increasing the p\(K_a\) of the endocyclic nitrogen and so making it protonated under physiological conditions. This protonated exocyclic nitrogen introduces a new ionic interaction with the catalytic aspartate residue discussed earlier. To further investigate this hypothesis, some fluorinated aminothiazoline analogues were synthesized (compounds 8a 8b and 8c). It is evident that increasing the number of fluorine atoms on the aminoethyl chain correlates with an increased \(K_i\) value.
The electron withdrawing fluorine atoms limit the ability of the exocyclic nitrogen to donate electrons to the endocyclic nitrogen, thereby decreasing the pKa of the endocyclic nitrogen and making it less likely to be present in a protonated form under physiological conditions. Furthermore, it is apparent that larger 2'-substituents are less tolerated than smaller groups, and groups above a certain size bind very poorly 4a-e.

Although the $K_i$ values for inhibitors of O-GlcNAcase are generally lower for those compounds containing less bulky exocyclic groups, it is important to incorporate some steric bulk attached to the thiazoline ring in order to maintain selectivity for O-GlcNAcase over the lysosomal $\beta$-hexosaminidases. Therefore, as will be discussed in greater detail, 1,2-dideoxy-2'-aminoethyl-$\alpha$-D-glucopyranosyl[2,1-$d$]-$\Delta^2$-thiazoline (Thiamet-G, compound 8g) was the inhibitor that gained most attention from our laboratory, despite there being two other inhibitors (compounds 8e and 8f) that had lower $K_i$ values than Thiamet-G against O-GlcNAcase. The lower $K_i$ values observed for 8e and 8f are most probably due to their having less bulky 2'-amino substituents. However, we expected these two inhibitors to be less selective for O-GlcNAcase over the $\beta$-hexosaminidases because of the lesser 2'-steric bulk. Indeed, Thiamet-G was the compound that still demonstrated potent inhibition of O-GlcNAcase while maintaining excellent selectivity (37,000-fold) for O-GlcNAcase over lysosomal $\beta$-hexosaminidases based on measurements made by Garrett Whitworth.107
2.8 Thiamet-G shows promise as a selective in vivo inhibitor and is a possible lead for Alzheimer disease treatment.

We were pleased to discover the inhibitory potency of Thiamet-G toward O-GlcNAcase. Thiamet-G showed superior binding affinity and selectivity ($K_i$ of 22 nM and 37,000 fold selectivity for human O-GlcNAcase over human lysosomal β-hexosaminidase) compared to the lead structure NButGT ($K_i = 600$ nM, selectivity for O-GlcNAcase over β-hexosaminidase enzymes is 700-fold).\textsuperscript{40} Thiamet-G was also shown by Scott Yuzwa to cross cellular membranes as well as being bioavailable.\textsuperscript{107}

In addition to this inhibitor being a potentially useful tool to study the effects of increased O-GlcNAcylation levels within cells, it also has potential as a lead to devise new therapeutics for Alzheimer disease.\textsuperscript{107} As mentioned in Chapter 1, Alzheimer disease has been correlated with increased levels of phosphorylation of the protein tau, a microtubule associated protein present in the central nervous system. Tau has been found to be hyperphosphorylated in Alzheimer disease. This high level of phosphorylation of tau is correlated with the formation of neurofibrillary tangles in the brain, which is one of the two main disease pathologies present in Alzheimer disease. In several cases it is known that the same, or nearby sites on proteins that are O-GlcNAc modified can also be phosphorylated.\textsuperscript{7,21} This is also likely true for tau, given the recent results found through studies performed by Scott Yuzwa in our laboratory as well as others.\textsuperscript{25,27,107} As a result, it seemed plausible that increasing O-GlcNAcylation on tau may successfully decrease levels of phosphorylation, thereby potentially contributing to slowing Alzheimer pathology at a molecular level. Upon
discovering Thiamet-G, investigation of these possibilities was quickly undertaken by talented biochemist colleagues, Yuzwa, Macauley, and Shan, in our laboratory. Although I will not discuss the biochemical details of the investigations, I will briefly summarize some of their results.

It was of interest to investigate in detail how Thiamet-G inhibits O-GlcNAcase at the molecular level. Because the structure of human O-GlcNAcase is not available, a structure of BtGH84, a bacterial homologue of O-GlcNAcase discussed previously, was used to investigate this issue. A crystal structure of Thiamet-G bound to BtGH84 was obtained by Prof. Gideon Davies and Rebecca Dennis from the University of York. The main difference between binding of Thiamet-G to O-GlcNAcase, compared to NBuGT, was the formation of the predicted interaction between the protonated endocyclic nitrogen of the thiazoline ring and the catalytic aspartate residue (Asp242 in BtGH84). The distances between the Asp242 and the endocyclic and exocyclic nitrogens of Thiamet-G are 2.7 and 2.8 Å, respectively. Figure 2.8 illustrates the interactions of BtGH84 with Thiamet-G:
Figure 2.8  Interactions between Thiamet-G with key residues of *BtGH84 O-GlcNAcase*.\textsuperscript{107}

Members of the Vocadlo laboratory carried out experiments to investigate whether Thiamet-G could successfully increase O-GlcNAc levels in cells. PC-12 cells were used, as they are a well characterized neuronal cell model. It was found that Thiamet-G inhibits O-GlcNAcase and increases O-GlcNAc levels in PC-12 cells in both a dose and time dependent manner. It was also found that Thiamet-G reduces tau phosphorylation at various residues in the same cell line.\textsuperscript{107} These findings have implications both in basic research as well as research relating to Alzheimer disease. The next big questions were whether administering Thiamet-G *in vivo* would have comparable results to those found in cells and whether Thiamet-G was capable of crossing the blood brain barrier within animals. In order to address these questions, Thiamet-G was administered intravenously at four different doses to Sprague Dawley rats (rats that are bred specifically for scientific research purposes). It was found that Thiamet-G is capable of crossing the blood brain barrier to increase brain O-GlcNAc levels in a dose dependent manner.\textsuperscript{107} It was also found that *in vivo* administration of
Thiamet-G reduces tau phosphorylation in all areas in the brains of treated rats. In the future Thiamet-G could be a valuable lead for generating potential therapeutics for Alzheimer disease as well as being a valuable stepping-stone to new discoveries. Currently, long term studies are underway in our laboratory to investigate the effect of Thiamet-G on tau pathology in animal models that show tau hyperphosphorylation and aggregation to form neurofibrillary tangles.

2.9 Methods

Several analogues (compounds 4a-e, 8a-g) were prepared using common synthetic methods. Section 2.9.1 describes the general methods used to synthesize the 2'-alkylthiazoline series (Scheme 2.1) and 2'-aminothiazoline series of inhibitors (Scheme 2.2). The yields and methods used to prepare each analogue are summarized in Figure 2.9.

2.9.1 Preparation of amides (2a-e) from compound (1).

Two methods were used to prepare amides 2a-e. The first method involved the use of $N,N'$-dicyclohexylcarbodiimide (DCC) or $N$-(3-dimethylaminopropyl)-$N'$-ethylcarbodiimide (EDC) (2.5 eq.) to couple the desired carboxylic acid (1.2 eq.) along with amine 1 (1 eq.). These reagents were suspended together in dimethylformamide (DMF) and upon addition of triethylamine (2 eq.) a homogeneous solution was obtained and the reaction was then stirred overnight. Upon completion of the reaction, as judged by TLC analysis, the crude reaction mixture was extracted with ethyl acetate. The organic fraction was then washed with saturated sodium bicarbonate, and brine.
Each aqueous layer was back extracted with ethyl acetate. The combined organic layers were dried using MgSO₄, filtered, and concentrated under vacuum. The crude residue was subjected to flash silica column chromatography using a solvent system of ethyl acetate and hexanes, in the appropriate ratio (typically 1:1), to afford the desired amides.

The second method to prepare amides 2a-e involved reaction of 1 (1 eq.) with the desired acid chloride (1.2 eq.) dissolved in DCM. N,N-diisopropylethylamine (2.2 eq.) was added to the mixture to act as a base. The reaction mixture was stirred (1.5 h), and upon completion of the reaction as judged by TLC analysis, it was diluted with DCM. The mixture was washed with saturated sodium bicarbonate, which was subsequently back extracted with DCM. The pooled organic layers were dried with MgSO₄, filtered, and concentrated under vacuum. The crude residue was subjected to flash silica column chromatography using a solvent system of an appropriate ratio of ethyl acetate and hexanes (typically 1:1), to obtain the desired amides.

2.9.2 Preparation of per-O-acetylated thiazoline analogues (3a-e) from (2a-e).

The general method used has been previously reported for related compounds, however some minor changes were made.¹³⁴ Each amide 2a-e (1 eq.) was suspended in toluene and Lawesson’s reagent (0.6 eq.) was added. The reaction mixture was heated (80-85 ºC) and stirred until the reaction was complete as judged by TLC analysis (2-3 h). The crude reaction mixture was concentrated in vacuo. The product was immediately purified by flash silica
column chromatography using an appropriate solvent system composed of ethyl acetate and hexanes (typically 1:1).\textsuperscript{40,134}

2.9.3 Preparation of deprotected thiazolines 4a-e.

The deprotected thiazolines were generated using procedures previously described in the literature for related compounds with minor modifications.\textsuperscript{40,107,134} A catalytic amount of anhydrous NaOMe or K\textsubscript{2}CO\textsubscript{3} was added to a solution of the protected thiazoline 3a-e. The resulting mixture (pH 9-10) was stirred until the reaction was judged complete by TLC analysis (typically 1 h). In cases where NaOMe was used, a solution of glacial acetic acid in methanol (pH 4) was added dropwise to the reaction mixture until the solution became neutral or slightly basic (pH 7-8). For reactions using K\textsubscript{2}CO\textsubscript{3}, the K\textsubscript{2}CO\textsubscript{3} was removed by filtration upon completion of the reaction. The solvent was removed under high vacuum at room temperature for both reaction methods. The desired products were isolated as syrups by flash silica column chromatography using a solvent system of DCM and methanol in ratios ranging from 5:1 to 10:1, as appropriate.

2.10 Aminothiazoline series: synthetic methods.

2.10.1 Preparation of isothiocyanate 5 from amine 1.

Isothiocyanate 5 was prepared as previously described with minor modifications.\textsuperscript{137} Amine 1 (8.44 g, 22.04 mmol, 1 eq.) and calcium carbonate (6.62 g, 66.1 mmol, 3 eq.) were combined, followed by addition of DCM (14 mL) and H\textsubscript{2}O (14 mL). Thiophosgene (3.80 g, 33.05 mmol, 1.5 eq.) was added drop
wise, followed by additional DCM (11 mL) and H₂O (11 mL). The mixture was stirred at room temperature (<1 h). The reaction mixture appeared bright yellow and separated into two immiscible layers once stirring ceased. The aqueous layer was back extracted with DCM. The combined organic layers were dried using MgSO₄, filtered, and concentrated to afford the crude product as a brownish yellow solid (6.87 g, 80%). ¹H-NMR data were consistent with the literature data for this previously known compound¹³⁷ and the material was used without further purification.

2.10.2 Preparation of thioureas 6a-g.

The preparation of thioureas 6a-g from isothiocyanate 5 was carried out in acetonitrile as the solvent and various desired hydrochloride salts of amines or free amines (1.2 eq.). When using 5 (1 eq.) and the hydrochloride salt of the desired amine as starting materials, triethylamine was also added to the reaction mixture (1.2 eq.). Reactions were stirred at room temperature until judged complete by TLC analysis (typically under 1 hr). The organic layer was washed with aqueous saturated sodium bicarbonate and the aqueous layer was subsequently back extracted with DCM. The combined organic layers were dried with MgSO₄, filtered, and concentrated under vacuum. The desired products were then purified from the crude residue by flash silica column chromatography using a solvent system composed of an appropriate ratio of ethyl acetate and hexanes (typically 1:1).
2.10.3 Preparation of the per-acetylated 2'-aminothiazoline derivatives 7a-g.

Thiourea derivatives 6a-g were cyclized to the corresponding thiazolines using the following general procedure: the thiourea derivative 6a-g was dissolved in DCM at room temperature. Acid was added to the solution, either SnCl₄ (4 eq.) or trifluoroacetic acid (7.5 eq.). The generation of related aminothiazoline compounds using Lewis acid catalysis was described previously.¹³¹ The reaction was stirred under an atmosphere of nitrogen until judged complete by TLC analysis (15 h). The reactions promoted using trifluoroacetic acid were washed twice with saturated aqueous sodium bicarbonate and the aqueous layers were back extracted three times with DCM. The combined organic fractions were dried with MgSO₄, filtered, and concentrated under vacuum. Reactions using SnCl₄ as a Lewis acid promoter were quenched with saturated sodium bicarbonate solution until the evolution of CO₂ from the reaction mixture ceased and the pH of the solution became neutral or slightly basic (pH 7-8). The resulting aqueous layer was extracted three times with DCM. The combined organic layers were dried with MgSO₄, filtered, and concentrated under vacuum. With both cyclization approaches the reactions were purified using flash silica column chromatography using a solvent system of an appropriate ratio of ethyl acetate and hexanes (typically 1:1).

2.10.4 Preparation of deprotected 2'-aminothiazoline analogues 8a-g.

Catalytic amounts of anhydrous K₂CO₃ were added to a solution of the appropriate 2'-aminothiazoline 7a-g. The basic solution was stirred under an atmosphere of N₂ until the reaction was judged complete by TLC analysis.
(typically 1 h). The reactions were filtered and the solvent was then removed under vacuum. The desired materials were isolated as syrups by flash silica column chromatography using a solvent system of DCM and methanol in ratios ranging from 5:1 to 10:1, as appropriate. The yields attained for each step of the analogue syntheses are summarized in Figure 2.9.
**Figure 2.9** Summary of synthetic methods and yields for twelve inhibitors of O-GlcNAcase.

Methods and yields are shown for each step used to prepare the different inhibitors. The general scaffold common to each analogue is illustrated at the top left of the table and the varying 'R' group functionalities are illustrated in the first column.

<table>
<thead>
<tr>
<th>'R' group attached via</th>
<th>Cyclized using</th>
<th>Deprotection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amine 1 reacted with 2-methoxyacetyl chloride (73%)</td>
<td>Lawesson's Reagent (16%)</td>
<td>catalytic NaOMe (52%)</td>
</tr>
<tr>
<td>Amine 1 reacted with 2-cyclopentylacetyl chloride (89%)</td>
<td>Lawesson's Reagent (89%)</td>
<td>catalytic NaOMe (quantitative)</td>
</tr>
<tr>
<td>Amine 1, benzoic acid reacted with EDC, DMAP (80%)</td>
<td>Lawesson's reagent (58%)</td>
<td>catalytic NaOMe (51%)</td>
</tr>
<tr>
<td>Amine 1, 4,4,4-trifluorobutanoic acid reacted with EDC, DMAP (80%)</td>
<td>Lawesson's reagent (39%)</td>
<td>catalytic NaOMe (51%)</td>
</tr>
<tr>
<td>Amine 1 reacted with 2-phenylacetic acid, EDC, DMAP (80%)</td>
<td>Lawesson's reagent (60%)</td>
<td>catalytic K₂CO₃ (46%)</td>
</tr>
<tr>
<td>Amine 1 reacted with isothiocyanatoethane, Et₃N (98%)</td>
<td>Tin (IV) Chloride (90%)</td>
<td>catalytic K₂CO₃ (quantitative)</td>
</tr>
<tr>
<td>Isothiocyanate 5 reacted methylanamine hydrochloride, Et₃N (62%)</td>
<td>Tin (IV) Chloride (76%)</td>
<td>catalytic K₂CO₃ (64%)</td>
</tr>
<tr>
<td>Isothiocyanate 5 reacted with 2-fluoroethylamine, Et₃N (62%)</td>
<td>Tin (IV) Chloride (44%)</td>
<td>catalytic K₂CO₃ (90%)</td>
</tr>
<tr>
<td>Isothiocyanate 5 reacted with 2,2-difluoroethylamine, Et₃N (56%)</td>
<td>Tin (IV) Chloride (75%)</td>
<td>catalytic K₂CO₃ (74%)</td>
</tr>
<tr>
<td>Isothiocyanate 5 reacted, 2,2,2-trifluoroethylamine, Et₃N (70%)</td>
<td>Tin (IV) Chloride (65%)</td>
<td>catalytic K₂CO₃ (47%)</td>
</tr>
<tr>
<td>Isothiocyanate 5 reacted, With dimethylamine hydrochloride, Et₃N (91%)</td>
<td>Trifluoroacetic acid (42%)</td>
<td>catalytic K₂CO₃ (75%)</td>
</tr>
<tr>
<td>Amine 1 reacted with 3-isothiocyanatoprop-1-ene, Et₃N (81%)</td>
<td>Trifluoroacetic acid (90%)</td>
<td>catalytic K₂CO₃ (18%)</td>
</tr>
</tbody>
</table>
2.11 Synthesized second generation inhibitors for O-GlcNAcase: NMR and elemental data.

The following data includes the structures and NMR data for the complete series of second generation inhibitors for O-GlcNAcase, as well as their synthetic intermediates, synthesized using the general procedures described in section 2.6.

4a

(2a) 1,3,4,6-Tetra-O-acetyl-2-[2-phenylacetyl)amino]-2-deoxy-β-D-glucopyranose

$^1$H-NMR (500 MHz, CDCl$_3$) δ (ppm) 7.33 (m, 2H), 7.27 (m, 1H), 7.21 (apparent triplet, $J = 7.1$ Hz, 2H), 5.65 (apparent triplet, $J = 8.9$ Hz, 2H), 5.10 (m, 2H), 4.23 (m, 2H), 4.10 (dd, $J = 12.5$, 2.1 Hz, 1H), 3.78 (m, 1H), 3.47 (s, 2H), 2.07 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H), 1.90 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 171.30, 171.12, 170.89, 169.56, 169.48, 134.60, 129.28, 129.26, 127.72, 92.57, 73.13, 72.32, 67.97, 61.85, 53.21, 44.19, 20.96, 20.95, 20.79, 20.71.

(3a) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-phenylmethyl-α-D-glucopyranosido[2,1-d]-Δ 2'-thiazoline

$^1$H-NMR (500 MHz, CDCl$_3$) δ (ppm) 7.23 (m, 5H), 6.16 (d, $J = 7.1$ Hz, 1H), 5.60 (m, 1H), 4.92 (d, $J = 9.4$ Hz, 1H), 4.52 (m, 1H), 4.08 (m, 1H), 3.96 (m, 2H), 3.76
(4a) 1,2- dideoxy-2'-phenylmethyl-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline

\(^1^H\)-NMR (500 MHz, MeOH, d\(_4\)) \(\delta\) (ppm) 7.27 (m, 5H), 6.34 (d, \(J = 7.0\) Hz, 1H), 4.36 (apparent triplet, \(J = 5.6\) Hz, 1H), 4.15 (apparent triplet, \(J = 4.9\) Hz, 1H), 3.85 (m, 1H), 3.7 (dd, \(J = 12.1, 1.3\) Hz, 1H), 3.62 (m, 2H), 3.35 (m, 2H); \(^{13}^C\)-NMR (125 MHz, MeOH, d\(_4\)) \(\delta\) (ppm) 174.36, 137.08, 130.21, 129.78, 128.34, 90.51, 80.09, 76.33, 74.38, 71.14, 63.31, 42.16; HRMS (m/z): [M+H]\(^+\) calcd for C\(_{14}\)H\(_{17}\)NO\(_4\)S: 296.0957; found 296.0964.

8a

(6a) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-[[([2-fluoroethyl)amino] thioxomethyl]amino]-β-D-glucopyranose

\(^1^H\)-NMR (500 MHz, CDCl\(_3\)) \(\delta\) (ppm) 6.64 (apparent triplet, \(J = 5.4\) Hz, 1H), 6.48 (d, \(J = 9.3\) Hz, 1H), 5.71 (d, \(J = 8.6\) Hz, 1H), 5.23 (apparent triplet, \(J = 9.7\) Hz, 1H), 5.09 (apparent triplet, \(J = 9.7\) Hz, 1H), 4.59 (m, 1H), 4.50 (m, 1H), 4.23 (dd, \(J = 12.5, 4.6\) Hz, 1H), 4.10 (m, 1H), 3.84 (m, 2H), 2.08 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H), 1.20 (t, \(J = 7.3\) Hz, 2H); \(^{13}^C\)-NMR (125 MHz, CDCl\(_3\)) \(\delta\) (ppm)
183.87, 171.52, 170.62, 169.34, 92.68, 83.01, 82.41 (d, J = 166.3 Hz, 1C),
72.87, 72.48, 67.76, 61.51, 60.30, 57.37, 20.90, 20.75, 20.60, 20.57.

(7a) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-(2-fluoroethyl)amino]-α-D-gluco
pyranosyl[2,1-d]-Δ2'-thiazoline

\[^1\text{H-NMR (500 MHz, CDCl}_3\] \(\delta\) (ppm) 6.21 (d, J = 6.5 Hz, 1H), 5.37 (apparent
triplet, \(J = 3.1\) Hz, 1H), 4.92 (dd, \(J = 9.5, 2.2\) Hz, 1H), 4.64 (m, 1H), 4.54 (m, 1H),
4.45 (m, 1H), 4.32 (dd, \(J = 6.3, 4.1\) Hz, 1H), 4.11 (m, 2H), 3.78 (m, 1H), 3.57 (m,
2H), 2.07 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H); \(^{13}\text{C-NMR (125 MHz, CDCl}_3\] \(\delta\) (ppm)
170.54, 169.51, 169.39, 89.34, 82.44 (d, \(J = 165.6\) Hz, 1C), 81.11, 71.62, 71.33,
68.78, 68.40, 63.07, 44.62, 20.84, 20.68, 20.62.

(8a) 1,2-dideoxy-2'-(2-fluoroethyl)amino]-α-D-glucopyranosyl[2,1-d]-Δ2'-thiazoline

\[^1\text{H-NMR (500 MHz, MeOH, d}_4\] \(\delta\) (ppm) 6.31 (d, \(J = 6.4\) Hz, 1H), 4.56 (m, 1H),
4.46 (m, 1H), 4.06 (apparent triplet, \(J = 6.1\) Hz, 1H), 3.92 (apparent triplet, \(J = 5.6\)
Hz, 1H), 3.78 (dd, \(J = 11.8, 2.1\) Hz, 1H), 3.56 (m, 5H); \(^{13}\text{C-NMR (125 MHz, MeOH, d}_4\] \(\delta\) (ppm)
163.19, 91.06, 91.04, 83.83 (d, \(J = 166.8\)Hz, 1C), 82.50,
76.34, 75.61, 71.12, 63.26; HRMS (m/z): \([\text{M+H}]^+\) calcd for C\(_9\)H\(_{15}\)FN\(_2\)O\(_4\)S:
267.0716 (M+H); found 267.0619.

\(8b\)
(6b) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-[[[(2,2-difluoroethyl)amino]thioxomethyl]amino]-β-D-glucopyranose

$^1$H-NMR (500 MHz, CDCl$_3$) $\delta$ (ppm) 6.69 (m, 2H), 5.94 (t, $J = 56.1$ Hz, 1H), 5.72 (d, $J = 8.6$ Hz, 1H), 5.23 (apparent triplet, $J = 10.1$ Hz, 1H), 5.09 (apparent triplet, $J = 9.6$ Hz, 1H), 4.21 (m, 1H), 4.06 (m, 2H), 3.95 (m, 1H), 3.84 (m, 2H), 2.06 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) $\delta$ (ppm) 184.55, 171.47, 170.81, 169.48, 113.36 (t, $J = 241.5$ Hz, 1C), 92.51, 72.82, 72.44, 67.84, 61.60, 60.38, 57.38, 20.68, 20.53, 20.52, 20.38.

(7b) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-(2,2-difluoroethyl)amino-α-D-gluco.pyranoso[2,1-d]-Δ2'-thiazoline

$^1$H-NMR (500 MHz, CDCl$_3$) $\delta$ (ppm) 6.22 (d, $J = 6.5$ Hz, 1H), 6.00 (m, 1H), 5.36 (m, 1H), 5.27 (s, 1H), 4.92 (m, 1H), 4.32 (m, 1H), 4.10 (m, 2H), 3.73 (m, 2H), 3.51 (m, 1H), 2.09 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) $\delta$ (ppm) 170.97, 169.88, 169.82, 159.97, 113.64 (t, $J = 241.2$ Hz, 1C), 90.36, 72.46, 71.62, 69.20, 68.67, 63.52, 21.18, 20.96, 20.94, 14.38.

(8b) 1,2-dideoxy-2'-(2,2-difluoroethyl)amino-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline

$^1$H-NMR (500 MHz, MeOH, d$_4$) $\delta$ (ppm) 6.34 (d, $J = 6.4$ Hz, 1H), 6.01 (m, 1H), 4.08 (m, 1H), 3.93 (apparent triplet, $J = 5.4$ Hz, 1H), 3.80 (dd, $J = 11.9$, 2.3 Hz, 1H), 3.56 (m, 5H); $^{13}$C-NMR (125 MHz, MeOH, d$_4$) $\delta$ (ppm) 205.31, 161.92, 114.22 (t, $J = 245.1$ Hz, 1C), 90.09, 75.17, 74.23, 69.85, 62.07; Elemental analysis calculated: C - 38.02, H - 4.96, N - 9.85; Found: C - 37.71, H - 5.00, N - 9.48.
(6c) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-[[[(2,2,2-trifluoroethyl)amino] thioxomethyl]amino]-β-D-glucopyranose

$^1$H-NMR (500 MHz, CDCl$_3$) δ (ppm) 6.74 (m, 2H), 5.73 (d, $J = 8.5$ Hz, 1H), 5.26 (apparent triplet, $J = 9.8$ Hz, 1H), 5.05 (apparent triplet, $J = 9.6$ Hz, 1H), 4.35 (m, 1H), 4.22 (m, 2H), 4.07 (m, 2H), 3.87 (m, 1H), 2.04 (s, 3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.98 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 184.84, 171.76, 171.63, 170.88, 169.62, 122.47 (q, $J = 279.3$ Hz, 1C) 92.44, 72.77, 72.42, 68.04, 61.66, 60.44, 57.52, 20.59, 20.52, 20.46, 20.36.

(7c) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-[(2,2,2-difluoroethyl)amino]-α-D-glucopyranosyl[2,1-d]-Δ2'-thiazoline

$^1$H-NMR (500 MHz, CDCl$_3$) δ (ppm) 6.20 (d, $J = 6.6$ Hz, 1H), 5.72 (s, 1H), 5.33 (dd, $J = 3.7$, 2.3 Hz, 1H), 4.87 (d, $J = 10.4$ Hz, 1H), 4.30 (dd, $J = 6.5$, 3.8 Hz, 1H), 4.04 (m, 3H), 3.80 (m, 1H), 3.74 (m, 1H), 2.05 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 170.58, 169.70, 169.40, 159.58, 124.01 (q, $J = 279.2$ Hz, 1C) 89.61, 71.51, 71.20, 68.82, 68.19, 63.10, 60.29, 20.75, 20.54, 20.50.

(8c) 1,2-dideoxy-2'-[(2,2,2-difluoroethyl)amino]-α-D-glucopyranosyl[2,1-d]-Δ2'-thiazoline
1H-NMR (500 MHz, MeOH, d4) δ (ppm) 6.35 (d, J = 6.4 Hz, 1H), 4.02 (m, 1H), 3.92 (m, 3H), 3.79 (dd, J = 11.9, 2.2 Hz, 1H), 3.68 (dd, J = 11.9, 6.1 Hz, 1H), 3.61 (m, 1H), 3.48 (dd, J = 9.1, 5.6 Hz, 1H); 13C-NMR (125 MHz, MeOH, d4) δ (ppm) 162.74, 126.16 (q, J = 277.9 Hz, 1C), 91.34, 76.59, 75.53, 71.07, 63.21, 45.13; HRMS (m/z): [M+H]⁺ calcd for C₉H₁₃O₄N₂SF₃ 303.0626 (M+1); found 303.0616.

(2b) 1,3,4,6-Tetra-O-acetyl-2-benzamido-2-deoxy-β-D-glucopyranose

1H-NMR (500 MHz, CDCl₃) δ (ppm) 7.69 (m, 2H), 7.40 (t, J = 7.4 Hz, 1H), 7.39 (t, J = 7.9 Hz, 2H), 6.52 (m, 1H), 5.80 (d, J = 8.8 Hz, 1H), 5.35 (apparent triplet, J = 10.7 Hz, 2H), 5.23 (t, J = 9.7 Hz, 1H), 4.60 (apparent triplet, J = 10.5 Hz, 1H), 4.30 (dd, J = 12.5, 4.8 Hz, 1H), 4.17 (dd, J = 12.5, 2.2 Hz, 1H), 2.11 (s, 3H), 2.07 (s, 3H), 2.07 (s, 3H), 2.00 (s, 3H); 13C-NMR (125 MHz, CDCl₃) δ (ppm) 171.61, 170.67, 169.59, 169.26, 167.31, 133.55, 131.96, 128.70, 128.67, 92.75, 73.06, 72.72, 67.79, 61.73, 53.15, 20.84, 20.72, 20.61, 20.57.

(3b) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-phenyl-α-D-glucopyranosyl[2,1-d]-Δ2'-thiazoline

1H-NMR (500 MHz, CDCl₃) δ (ppm) 7.87, (d, J = 7.1 Hz, 2H), 7.52 (t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 6.38 (d, J = 7.1 Hz, 1H), 5.74 (dd, J = 3.3, 1.6 Hz,
1H), 5.00 (d, J = 9.4 Hz, 1H), 4.75 (m, 1H), 4.13 (m, 2H), 3.62 (m, 1H), 2.19 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H); 13C-NMR (125 MHz, CDCl₃) δ (ppm) 169.50, 109.59, 109.09, 102.86, 77.63, 77.56, 76.77, 67.04, 66.75, 54.08, 52.57, 48.87, 26.79, 26.72, 26.11, 25.00, 22.91.

(4b) 1,2-dideoxy-2'-phenyl-α-D-glucopyranosyl[2,1-d]-Δ2'-thiazoline

1H-NMR (500 MHz, MeOH, d₄) δ (ppm) 7.85 (d, J = 7.2 Hz, 2H), 7.51 (m, 1H), 7.45 (m, 2H), 6.49 (s, J = 6.9 Hz, 1H), 4.58 (dd, J = 6.7, 5.2 Hz, 1H), 4.26 (apparent triplet, J = 4.5 Hz, 1H), 3.76 (dd, J = 12.1, 2.5 Hz, 1H), 3.63 (m, 2H), 3.42 (m, 1H); 13C-NMR (125 MHz, MeOH, d₄) δ (ppm) 169.25, 133.32, 131.57, 128.52, 128.18, 88.87, 80.21, 75.38, 73.35, 70.27, 62.27; Elemental analysis calculated: C -55.10, H - 5.37 N - 4.98; Found: C - 54.79, H - 5.65, N - 4.95.

(6d) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-[[[2-prop-1-ene)amino]thioxomethyl]amino]-β-D-glucopyranose

1H-NMR (500 MHz, CDCl₃) δ (ppm) 6.48 (s, 2H), 5.77 (s, 1H), 5.71 (d, J = 8.6 Hz, 1H), 5.24 (s, 2H), 5.11 (m, 3H), 4.22 (dd, J = 12.5, 4.6 Hz, 1H), 4.05 (m, 2H), 3.80 (m, 1H), 2.05 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H), 1.19 (m, 1H); 13C-NMR (125 MHz, CDCl₃) δ (ppm) 211.43, 171.85, 171.00, 169.60, 93.16, 73.21, 73.07, 68.00, 61.90, 57.94, 21.30, 21.10, 21.00, 20.85.
(7d) 3,4,6-Tri-\textit{O}-acetyl-1,2-dideoxy-2'-[(2-prop-1-ene)amino]-\alpha-\textit{D}-gluco-
pyranoso[2,1-\textit{d}]-\Delta^2'-thiazoline

\(^1\)H-NMR (500 MHz, CDCl\(_3\)) \(\delta\) (ppm) 6.34 (s, 1H), 6.16 (d, \(J = 6.6\) Hz, 1H), 5.81 (m, 1H), 5.31 (apparent triplet, \(J = 3.3\) Hz, 1H), 5.16 (d, \(J = 17.2\) Hz, 1H), 5.06 (d, \(J = 11.3\) Hz, 1H), 4.83 (dd, \(J = 9.4, 2.4\) Hz, 1H), 4.27 (dd, \(J = 6.0, 4.8\) Hz, 1H), 4.02 (m, 2H), 3.81 (m, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.97 (s, 3H); \(^{13}\)C-NMR (125 MHz, CDCl\(_3\)) \(\delta\) (ppm) 170.36, 169.38, 169.38, 159.98, 133.93, 116.06, 89.30, 72.25, 71.53, 68.88, 68.12, 62.97, 46.51, 20.71, 20.58, 20.49.

(8d) 1,2-dideoxy-2'-[(2-prop-1-ene)amino]-\alpha-\textit{D}-glucopyranoso[2,1-\textit{d}]-\Delta^2'-
thiazoline

\(^1\)H-NMR (500 MHz, CDCl\(_3\)) \(\delta\) (ppm) 6.31 (d, \(J = 6.4\) Hz, 1H), 5.90 (m, 1H), 5.22 (m, 1H), 5.11 (m, 1H), 4.06 (apparent triplet, \(J = 4.1\) Hz, 1H), 3.92 (apparent triplet, \(J = 5.6\) Hz, 1H), 3.86 (m, 2H), 3.78 (dd, \(J = 11.7, 2.1\) Hz, 1H), 3.63 (m, 2H), 3.47 (dd, \(J = 8.9, 5.3\) Hz, 1H); \(^{13}\)C NMR (125 MHz, MeOH, d\(_4\)) \(\delta\) (ppm) 163.37, 135.89, 116.23, 90.95, 76.46, 75.57, 71.28, 63.35, 47.22; HRMS (m/z): [M+H]\(^+\) calcd for C\(_{10}\)H\(_{16}\)N\(_2\)O\(_4\)S: 261.0909 (M+H); found 261.0909.
(6e) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2'[[[dimethylamino]thioxomethyl]amino]-β-D-glucopyranose$^{140}$

$^1$H NMR (500 MHz, CDCl$_3$) δ (ppm) 5.77 (d, $J = 8.4$ Hz, 1H), 5.72 (d, $J = 9.2$ Hz, 1H), 5.31 (dd, $J = 18.5, 9.4$ Hz, 1H), 5.20 (m, 2H), 4.22 (dd, $J = 12.5, 4.7$ Hz, 1H), 4.10 (m, 1H), 3.81 (m, 1H), 3.17 (s, 6H), 2.08 (s, 3H), 2.06 (s, 3H), 2.02 (s, 3H), 2.00 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 182.29, 171.83, 170.68, 169.94, 169.06, 93.28, 73.24, 72.99, 67.52, 61.71, 58.46, 40.63, 21.06, 20.78, 20.69, 20.53.

(7e) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-dimethylamino-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline$^{140}$

$^1$H NMR (500 MHz, CDCl$_3$) δ (ppm) 6.35 (d, $J = 6.7$ Hz, 1H), 5.32 (apparent triplet, $J = 5.3$ Hz, 1H), 4.92 (dd, $J = 9.5, 5.1$ Hz, 1H), 4.42 (apparent triplet, $J = 6.1$ Hz, 1H), 4.08 (m, 2H), 3.92 (m, 1H), 3.10 (s, 6H), 2.02 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H); $^{13}$C NMR (125 MHz, CDCl$_3$) δ (ppm) 170.48, 169.89, 169.38, 87.73, 70.77, 69.76, 67.25, 65.65, 62.14, 49.83, 41.22, 20.41, 20.36, 20.35.

(8e) 1,2-dideoxy-2'-dimethylamino-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline$^{140}$

$^1$H NMR (500 MHz, MeOH, d$_4$) δ (ppm) 6.38 (d, $J = 6.5$ Hz, 1H), 4.07 (apparent triplet, $J = 6.3$ Hz, 1H), 3.87 (apparent triplet, $J = 6.1$ Hz, 1H), 3.81 (dd, $J = 11.5, 1.6$ Hz, 1H), 3.65 (m, 2H), 3.48 (dd, $J = 6.0$ Hz, 1H), 3.04 (s, 6H); $^{13}$C NMR (125 MHz, MeOH, d$_4$) δ (ppm) 166.48, 91.82, 76.54, 75.78, 74.68, 70.76, 62.95, 40.40; HRMS (m/z): [M+H]$^+$ calcd for C$_9$H$_{16}$N$_2$O$_4$S: 249.0909 (M+H); found 249.0912.
(2c) 1,3,4,6-Tetra-O-acetyl-2-cyclopropaneacetamido-2-deoxy-β-D-gluco pyranose

\(^1\)H NMR (500 MHz, CDCl\(_3\)) \(\delta\) (ppm) 6.22 (d, \(J = 9.6\) Hz, 1H), 5.70 (d, \(J = 8.8\) Hz, 1H), 5.21 (apparent triplet, \(J = 9.5\) Hz, 1H), 5.10 (apparent triplet, \(J = 9.9\) Hz, 1H), 4.09 (dd, \(J = 20.1, 10.5\) Hz, 1H), 4.23 (dd, \(J = 12.5, 4.8\) Hz, 1H), 4.09 (dd, \(J = 12.4, 2.1\) Hz, 1H), 3.83 (m, 1H), 2.07 (s, 3H), 2.05 (s, 3H), 2.03 (d, \(J = 7.2\) Hz, 2H), 2.01 (s, 3H), 2.00 (s, 3H), 0.85 (m, 1H), 0.51 (m, 2H), 0.10 (m, 2H); \(^{13}\)C-NMR (125 MHz, CDCl\(_3\)) \(\delta\) (ppm) 172.51, 171.00, 170.57, 169.36, 169.20, 92.46, 72.75, 72.40, 67.86, 61.67, 52.44, 41.42, 20.75, 20.61, 20.55, 20.46, 7.11, 4.42, 4.38.

(3c) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-cyclopropylmethyl-α-D-glucopyranoso [2,1-d]-Δ2'-thiazoline

\(^1\)H NMR (500 MHz, CDCl\(_3\)) \(\delta\) (ppm) 6.19 (d, \(J = 7.1\) Hz, 1H), 5.55 (dd, \(J = 3.3, 1.6\) Hz, 1H), 4.70 (d, \(J = 9.5\) Hz, 1H), 4.46 (m, 1H), 4.07 (m, 2H), 3.54 (m, 1H), 2.43 (m, 2H), 2.10 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 0.99 (m, 1H), 0.55 (m, 2H), 0.22 (m, 2H); \(^{13}\)C-NMR (125 MHz, CDCl\(_3\)) \(\delta\) (ppm) 172.64, 170.47, 169.45, 169.19, 87.83, 76.02, 70.53, 69.24, 68.26, 63.31, 39.42, 20.89, 20.79, 20.65, 9.17, 5.01, 4.61.
(4c) 1,2-dideoxy-2'-cyclopropylmethyl-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline

\(^1\)H NMR (500 MHz, MeOH, d\(_4\)) δ (ppm) 5.90 (d, J = 7.0 Hz, 1H), 4.10 (apparent triplet, J = 5.5 Hz, 1H), 3.92 (apparent triplet, J = 4.1 Hz, 1H), 3.52 (dd, J = 12.0, 2.5 Hz, 1H), 3.38 (m, 2H), 3.14 (m, 1H), 2.23 (d, J = 7.2 Hz, 2H), 0.77 (m, 1H), 0.35 (d, J = 7.9 Hz, 2H), 0.03 (m, 2H); \(^1\)C NMR (125 MHz, MeOH, d\(_4\)) δ (ppm) 175.52, 89.74, 79.81, 76.18, 74.18, 71.22, 63.39, 40.52, 10.08, 5.51, 5.40; Elemental analysis calculated: C - 50.95, H - 6.61, N - 5.40; Found: C - 50.65, H - 6.59, N - 5.39.

(2d) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-(4,4,4-trifluorobutanamido)-β-D-gluco pyranose

\(^1\)H NMR (500 MHz, CDCl\(_3\)) δ (ppm) 5.90 (d, J = 9.4 Hz, 1H), 5.72 (d, J = 8.8 Hz, 1H), 5.18 (m, 2H), 4.29 (m, 1H), 4.12 (dd, J = 12.5, 2.1 Hz, 1H), 3.82 (m, 1H), 2.47 (m, 2H), 2.36 (m, 2H), 2.09 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.72 (s, 1H); \(^1\)C NMR (125 MHz, CDCl\(_3\)) δ (ppm) 171.36, 170.66, 169.91, 169.51, 169.28, 92.44, 72.84, 72.47, 67.75, 61.61, 53.10, 29.36 (q, J = 30.1 Hz, 1C) 20.78, 20.71, 20.57, 20.56.
(3d) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2′-(3,3,3-trifluoropropyl)-α-D-gluco pyranoso[2,1-d]-Δ2′-thiazoline

$^1$H NMR (500 MHz, CDCl$_3$) $\delta$ (ppm) 6.30 (d, $J =$ 7.2, 1H), 5.58 (m, 1H), 4.96 (dd, $J =$ 9.3, 1.3 Hz, 1H), 4.51 (m, 1H), 4.14 (m, 2H), 3.53 (m, 1H), 2.83 (m, 2H), 2.58 (m, 2H), 2.16 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) $\delta$ (ppm) 170.57, 169.47, 169.31, 168.87, 88.65, 76.18, 70.31, 69.10, 68.46, 63.26, 31.14, 30.90 (q, $J =$ 30.1 Hz, 1C), 27.19, 20.95, 20.78, 20.72.

(4d) 1,2-dideoxy-2′-(3,3,3-trifluoropropyl)-α-D-glucopyranoso[2,1-d]-Δ2′-thiazoline

$^1$H NMR (500 MHz, MeOH, d$_4$) $\delta$ (ppm) 6.40 (d, $J =$ 7.0 Hz, 1H), 4.35 (m, 1H), 4.15 (apparent triplet, $J =$ 3.9 Hz, 1H), 3.74 (dd, $J =$ 12.1, 2.4 Hz, 1H), 3.59 (m, 2H), 3.32 (m, 1H), 2.80 (m, 2H), 2.60 (m, 2H); $^{13}$C NMR (125 MHz, MeOH, d$_4$) $\delta$ (ppm) 207.59, 171.17, 90.71, 80.43, 76.31, 74.07, 71.27, 63.47, 32.12 (q, $J =$ 30.9 Hz, 1C), 28.43; Elemental analysis calculated: C -39.87, H - 4.68, N - 4.65; Found: C - 39.90, H - 4.65, N - 4.58.

(2e) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-methoxyacetamido-β-D-gluco pyranose

$^1$H NMR (500 MHz, CDCl$_3$) $\delta$ (ppm) 6.58 (d, $J =$ 9.6 Hz, 1H), 5.75 (d, $J =$ 8.7 Hz, 1H), 10.33 (apparent triplet, $J =$ 10.3 Hz, 1H), 5.12 (apparent triplet, $J =$ 9.8 Hz,
1H), 4.27 (m, 1H), 4.14 (dd, J = 12.4, 2.1 Hz, 1H), 3.82 (m, 3H), 3.36 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.68 (s, 1H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 170.64, 170.60, 169.98, 169.29, 92.28, 72.82, 72.17, 71.63, 67.76, 61.57, 59.29, 52.34, 20.87, 20.71, 20.58, 20.57.

(3e) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-methoxymethyl-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline

$^1$H NMR (500 MHz, CDCl$_3$) δ (ppm) 6.18 (d, J = 7.3 Hz, 1H), 5.53 (dd, J = 3.3, 1.8 Hz, 1H), 4.89 (d, J = 9.4 Hz, 1H), 4.48 (m, 1H), 4.32 (dd, J = 14.3, 2.3 Hz, 1H), 4.22 (dd, J = 14.3, 2.4 Hz, 1H), 4.06 (m, 2H), 3.49 (m, 1H), 3.40 (s, 3H), 2.08 (s, 3H), 2.02 (s, 6H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 171.59, 170.29, 169.23, 169.01, 86.59, 76.06, 71.51, 70.25, 68.97, 68.28, 63.05, 59.01, 20.72, 20.61, 20.50.

(4e) 1,2-dideoxy-2'-methoxymethyl-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline

$^1$H NMR (500 MHz, MeOH, d$_4$) δ (ppm) 6.37 (d, J = 6.9 Hz, 1H), 5.41 (m, 1H), 4.99 (m, 1H), 4.44 (m, 1H), 4.38 (apparent triplet, J = 5.6 Hz, 1H), 4.26 (m, 2H), 4.11 (s, 1H), 3.78 (m, 1H), 3.41 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 173.22, 88.66, 77.90, 74.56, 73.41, 71.93, 68.90, 61.57, 59.36; HRMS (m/z): [M+H]$^+$ calcd for C$_9$H$_{15}$NO$_5$S: 250.0749 (M+H); Found: 250.0777.
(6f) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-[[[aminomethyl]thioxomethyl]amino]-β-D-glucopyranose

\(^1\)H NMR (500 MHz, CDCl\(_3\)) \(\delta\) (ppm) 6.21 (s, 1H), 5.92 (s, 1H), 5.74 (d, \(J = 8.1\) Hz, 1H), 5.20 (m, 2H), 4.28 (dd, \(J = 12.5, 4.6\) Hz, 1H), 4.13 (m, 2H), 3.84 (m, 1H), 2.98 (s, 3H), 2.15 (s, 3H), 2.11 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H); \(^{13}\)C-NMR (125 MHz, CDCl\(_3\)) \(\delta\) (ppm) 171.78, 171.03, 169.81, 169.65, 93.01, 73.35, 72.90, 68.14, 62.00, 57.68, 53.76, 21.22, 21.03, 20.94, 20.80.

(7f) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-aminomethyl-α-D-glucopyranosyl[2,1-d]-Δ2'-thiazoline

\(^1\)H NMR (500 MHz, CDCl\(_3\)) \(\delta\) (ppm) 6.21 (d, \(J = 6.5\) Hz, 1H), 5.39 (dd, \(J = 4.1, 2.9\) Hz, 1H), 4.90 (m, 1H), 4.34 (dd, \(J = 6.2, 4.3\) Hz, 1H), 4.12 (m, 2H), 3.84 (m, 1H), 2.90 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H); \(^{13}\)C-NMR (125 MHz, CDCl\(_3\)) \(\delta\) (ppm) 170.89, 169.90, 169.72, 161.21, 90.03, 73.01, 72.24, 69.40, 68.67, 63.40, 31.19, 21.23, 21.10, 21.00.

(8f) 1,2-dideoxy-2'-aminomethyl-α-D-glucopyranosyl[2,1-d]-Δ2'-thiazoline

\(^1\)H NMR (500 MHz, MeOH, \(d_4\)) \(\delta\) (ppm) 6.14 (d, \(J = 6.4\) Hz, 1H), 4.04 (t, \(J = 5.1\) Hz, 1H), 3.90 (t, \(J = 5.1\) Hz, 1H), 3.67 (m, 1H), 3.51 (m, 2H), 3.42 (m, 1H), 2.67 (s, 3H); \(^{13}\)C NMR (125 MHz, MeOH, \(d_4\)) \(\delta\) (ppm) 163.73, 88.52, 74.19, 73.61, 73.24, 69.28, 61.39, 29.83; HRMS (m/z): [M+H]\(^+\) calcd for C\(_8\)H\(_{14}\)N2O\(_4\)S: 235.0674 (M+H); Found: 234.0753.
(6g) 1,3,4,6-Tetra-O-acetyl-2-deoxy-2-[[[(aminoethyl)thioxomethyl]amino]-β-D-glucopyranose

$^1$H NMR (500 MHz, CDCl$_3$) δ (ppm) 6.12 (d, $J = 15.0$ Hz, 1H), 6.00 (s, 1H), 5.73 (d, $J = 7.7$ Hz, 1H), 5.19 (m, 1H), 4.81 (s, 1H), 4.28 (m, 1H), 4.12 (m, 1H), 3.85 (m, 1H), 3.40 (s, 1H), 2.14 (s, 3H), 2.10 (s, 3H), 2.08 (s, 3H), 2.05 (s, 3H), 1.81 (d, $J = 40.2$ Hz, 1H), 1.19 (m, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 171.88, 170.97, 169.60, 163.03, 93.12, 73.31, 72.99, 68.08, 61.95, 60.67, 57.84, 21.25, 21.07, 20.96, 20.81, 14.39.

(7g) 3,4,6-Tri-O-acetyl-1,2-dideoxy-2'-aminoethyl-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline

$^1$H NMR (500 MHz, CDCl$_3$) δ (ppm) 6.24 (d, $J = 6.5$ Hz, 1H), 5.43 (dd, $J = 4.0, 2.7$ Hz, 1H), 4.96 (m, 1H), 4.37 (m, 1H), 4.14 (d, $J = 4.3$ Hz, 2H), 3.85 (m, 1H), 3.34 (m, 2H), 2.12 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 1.22 (t, $J = 7.1$ Hz, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 171.88, 170.97, 169.60, 93.12, 73.31, 72.99, 68.08, 61.95, 57.84, 21.25, 21.07, 20.96, 20.81, 14.28.

(8g) 1,2-dideoxy-2'-aminoethyl-α-D-glucopyranoso[2,1-d]-Δ2'-thiazoline

$^1$H NMR (500 MHz, MeOH, d$_4$) δ (ppm) 6.44 (d, $J = 6.4$ Hz, 1H), 4.09 (apparent triplet, $J = 6.4$ Hz, 1H), 3.89 (apparent triplet, $J = 6.2$ Hz, 1H), 3.82 (dd, $J = 11.7$, $J = 2.0$ Hz, 1H).
1.8 Hz, 1H), 3.66 (m, 2H), 3.49 (dd, $J = 9.0, 6.1$ Hz, 1H), 3.35 (m, 2H), 1.22 (t, $J = 7.3$ Hz, 3H); $^{13}$C NMR (125 MHz, MeOH, d$_4$) $\delta$ (ppm) 161.92, 89.72, 75.11, 74.57, 69.99, 62.07, 38.40, 38.35, 13.73; Elemental analysis calculated: C -43.53, H - 6.49, N - 11.28; Found: C - 43.82, H -6.62, N - 11.02.

2.12 Kinetic analysis of potent inhibitors using 4-methylumbelliferyl 2-acetamido-2-deoxy-β-D-glucopyranoside as a substrate.

Assays were carried out at 37 °C using 4-methylumbelliferyl 2-acetamido-2-deoxy-β-D-glucopyranoside as a substrate in a continuous assay where the linear rate of liberation of 4-methylumbelliferone was monitored by measuring its fluorescence emission (450 nm) using a CARY Eclipse fluorometer equipped with a temperature controller. Reactions (final volume of 150 μL) were initiated by the addition, via syringe, of enzyme (10 μL, 1.3X10$^{-4}$ μg/μL final concentration) and monitored for 3 minutes. Recombinant human O-GlcNAcase is stable in the assay buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na$_2$HPO$_4$, 2 mM K$_2$HPO$_4$, with ~0.1% BSA) over the time of the assay. The inhibitors of interest were tested at 6 or more concentrations above and below the estimated $K_i$ value. The $K_i$ values were determined by Dixon plot analysis.

2.13 Kinetic analysis of moderate to poor inhibitors using 4-nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside (pNP-GlcNAc) as a substrate

Assays were carried out in triplicate at 37 °C in a Precision incubator, using 4-nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside (pNP-GlcNAc) as
a substrate in a stopped assay procedure. Absorbance values produced by the liberated 4-nitrophenolate were recorded at 400 nm using a Spectra max 340 spectrophotometer. Reactions (final volume of 50 μL) were initiated by the addition, via syringe, of enzyme (5 μL, to generate a final concentration of enzyme between 1.8X10^-5 μg/μL and 9.0 X10^-4 μg/μL) and were allowed to react for 30 minutes. Enzymatic reactions were stopped by the addition of 200 μL basic glycine quenching buffer (0.1M glycine, 1mM Zn2Cl, 1mM MgCl2, pH adjusted to 10.4 using 10 N NaOH). Absorbance values were determined from aliquots (100 μL) taken from the quenched reactions and subtracting the value obtained for a reaction containing no enzyme. Recombinant human O-GlcNAcase is stable in the assay buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM K2HPO4, with ~0.1% BSA) over the time of the assay. The inhibitors of interest were tested at 6 or more concentrations above and below the estimated K_i value. The K_i values were determined by Dixon plot analysis.
Chapter 3: Synthesis of 2-acetamido-2-deoxy-5-thio-α-D-glucopyranose (5SGlcNAc) and derivatives.

3.1 Synthesis of 2-acetamido-2-deoxy-5-thio-α-D-glucopyranose (5SGlcNAc).

3.1.1 Rationale behind the synthesis of 5SGlcNAc.

As discussed in chapter 2, a bacterial homologue of O-GlcNAcase, \( \textit{Bt} \text{GH84} \), has been characterized fairly comprehensively.\(^{40,41,128,129,142,143} \) Several studies have also clarified aspects of the catalytic mechanism and the natural function of O-GlcNAcase in cells. There remains, however, much to discover about how O-GlcNAcase is regulated in cells as well as its specific roles in certain diseases. Further studies to better understand its substrate specificity and detailed catalytic mechanism are also warranted. In this regard, investigating how tolerant O-GlcNAcase is to variation in substrate structure may provide further insight into its catalytic mechanism. It is also worth noting that sometimes molecules resembling the natural substrate, intermediate, or transition state can act as inhibitors of enzymes. For these reasons, studying substrate analogues for O-GlcNAcase was judged worthwhile and synthetic derivatives of 2-acetamido-2-deoxy-5-thio-D-glucopyranose (5SGlcNAc) were prepared. 5SGlcNAc differs from the natural substrate of O-GlcNAcase in that the endocyclic ring oxygen is replaced by sulphur (Figure 3.1).

78
3.2 Results and Discussion: synthetic challenges and triumphs

3.2.1 Synthesis of 5SGlcNAc (18)

Despite the availability of published methods,\textsuperscript{144,145} the synthesis of the target (5SGlcNAc, 18)\textsuperscript{144,145} was not trivial and the published methodology we followed was modified in order to obtain improved results. The procedures used are outlined in Scheme 3.1.

For the synthesis of 2-acetamido-2-deoxy-3,4:5,6-di-O-isopropylidene-aldehydo-D-glucose diethyl acetal (10), it was found that a much longer reaction time was required (24 h) than was quoted in the literature (2 h) in order to obtain comparable yields.\textsuperscript{145} Additionally, at this step, rather than using a basic resin, potassium carbonate was added directly to the crude reaction mixture to neutralize the solution once the reaction was judged complete by TLC. It was found that to effect the benzylation of 2-acetamido-2-deoxy-3,4-O-isopropylidine-aldehydo-D-glucose dimethyl acetal (11) to generate 2-acetamido-6-O-benzyol-2-deoxy-3,4-O-isopropylidene-aldehydo-D-glucose dimethyl acetal (12), it was imperative that the reaction was carried out under dry conditions. Any moisture resulted in poor yields and the formation of undesired by-products.
Mesylation of intermediate 12 resulted in a good yield of 2-acetamido-6-O-
benzoyl-2-deoxy-3,4-O-isopropylidine-5-O-mesy aldehyde-D-glucose dimethyl
acetal (13). For both reactions, the already purified starting material was placed
under high vacuum for at least 3 hours prior to setting up the reaction under an
atmosphere of N₂.

Scheme 3.1 Synthesis of Ac-5SGlcNAc (17) and 5SGlcNAc (18).

a) 2,2 Dimethoxypropane, p-tosic acid, dioxane, 80 °C, 24 h; b) 80% AcOH in H₂O,
40 °C, 2 h; c) Benzoyl chloride, pyridine, -20 °C, 6 h; d) Methane sulphonyl chloride,
pyridine, 0 °C, 2 h; e) NaOMe, DCM -20 → 0 °C, 2 h; f) Thiourea, MeOH, 60 °C, 2 h;
g) KOAc, AcOH, acetic anhydride, 160 °C, 20 h; h) 10:1 NaOAc, 10 M HCl, 40 °C,
24 h; i) Acetic anhydride, pyridine, 0 °C, 12 h; j) MeOH, NaOMe, r.t, 1h; k) AcOH,
MeOH (pH 4).144,145
Synthesis of the epoxide, 2-acetamido-5,6-anhydro-2-deoxy-3,4-O-isopropylidene-aldehydo-L-idose dimethyl acetal (14), was relatively straightforward, however, care was required when neutralizing the basic reaction mixture with the acidic resin. If the reaction pH became even slightly acidic, degradation of product occurred rapidly upon concentrating the crude mixture in vacuo. Therefore, if needed, potassium carbonate was used to neutralize the pH if too much acidic resin had been added to the crude reaction mixture at this step. To successfully synthesize the thioepoxide, it was crucial that all glassware and reagents were dry. Drying the starting material 14, as well as the thiourea, for several hours under high vacuum was required to obtain good yields.

The opening of the thioepoxide to generate intermediate 16 proved to be an extremely challenging step, and 72% was the best yield obtained. The key to increasing the yield of this reaction was a high reaction temperature (160 °C) and long (15-20 h) reaction time. Optimization of the global deprotection / reprotection step to yield per-O-acetylated 5SGlcNAc 17 was difficult. When following literature procedures,144 poor yields were obtained (10-20%). It was found that a long reaction time (24 h) was required. The literature procedure144 reports a 6 hour reaction time for this step, but to obtain comparable yields (75%) required at least 15 hour reaction time. Additionally, the desired material degraded when concentrating this reaction in vacuo with the application of heat; using high vacuum rotary evaporation without heating was needed to obtain the desired material in good yield. Acetylation of the crude product was achieved in a similar manner as described in the literature.144 Again, concentrating the crude product
was successfully accomplished using high vacuum rotary evaporation with no heating. The final deprotection step was affected using the literature procedure.\textsuperscript{144} It seems, however, that this product is also heat sensitive and isolation requires gradual concentration of only pure fractions obtained from column chromatography, to yield crystalline white needles.

3.2.2 5SGlcNAc: a possible metabolic inhibitor of the glycosyl transferase, OGT.

After purifying 5SGlcNAc, it was decided that it would be interesting to investigate whether this material would produce any measurable effects in cells. One scenario envisioned was that 5SGlcNAc might be incorporated in the place of O-GlcNAc on cellular proteins and accumulate, since it might be turned over slowly by O-GlcNAcase. Another scenario considered possible, though less likely, was that O-GlcNAc levels on proteins might drop; OGT might install 5SGlcNAc more slowly than GlcNAc and O-GlcNAcase might remove 5SGlcNAc more quickly than it is in-stalled. Interestingly, when Dr. Tracey Gloster (from our laboratory) treated cells with 5SGlcNAc, significant decreases in O-GlcNAc levels were observed. This led to the hypothesis that 5SGlcNAc is converted to uridine diphosphate 2-acetamido-2-deoxy-5-thio-\(\alpha\)-d-glucopyranoside (UDP-5SGlcNAc, compound \textbf{19}, Figure 3.2) and this molecule might act as an inhibitor of OGT.
This observation and hypothesis was of great interest to our laboratory as there were no known cell permeable inhibitors of OGT, and the discovery of such a compound would be both novel and useful for research into understanding the role of O-GlcNAc in cells. Because O-GlcNAc modification levels have been implicated in several disease states, discovering a way of decreasing the levels of O-GlcNAc in cells could provide a means of investigating the molecular basis for involvement of O-GlcNAc in these diseases as well as its normal biological roles. This could be done by treating cells, and perhaps even animals, with this compound. To verify whether the results observed in cells were due to UDP-5SGlcNAc blocking OGT, Wesley Zandberg and Dr. Tracey Gloster chemoenzymatically synthesized this compound using the 5SGlcNAc that had been prepared. With this compound in hand, kinetic studies were undertaken by Dr. Tracey Gloster and David Shen in our laboratory to evaluate this compound as an inhibitor of OGT. To our excitement, it was found that UDP-5SGlcNAc did inhibit OGT with a $K_i$ value of 8 μM. UDP-5SGlcNAc was also evaluated as a substrate for OGT and it was found that it was a poor substrate compared to UDP-GlcNAc.


Even though UDP-5SGlcNAc (19) was a poor substrate for OGT, and therefore transfers to proteins only very slowly, we were interested in studying whether glycosides of 5SGlcNAc could be substrates for O-GlcNAcase. Creating a β-glycoside of 5SGlcNAc presented several obstacles. The first approach to preparing such a substrate was to generate the glycosyl donor 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride (Compound 20, Scheme 3.2). Reflecting on previous work done in our laboratory where the synthesis of 2-acetamido-2-deoxy-β-D-glucopyranosides from 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride was successfully achieved, we expected that the analogous 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranosyl chloride (20) could be used to stereoselectively prepare 5-thio-β-D-N-acetylglucopyranosides. The basis for stereoselectivity was that the 2-acetamido group should provide anchimeric assistance to block the bottom face of a glycosyl cation intermediate such that nucleophilic attack occurs predominantly on the β-face of the pyranose ring. A β-configured glycoside is essential for testing as a substrate of O-GlcNAcase since this enzyme only catalyzes hydrolysis of β-glycosides. An α-configured product would thus be useless for testing as a substrate of O-GlcNAcase.

For the reasoning stated above, the synthesis of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranosyl chloride (20) was undertaken using
conditions previously used for the synthesis of the oxygen analogue\textsuperscript{146} (see methods section for reaction conditions and Scheme 3.2). After successful synthesis of the glycosyl donor 20, several glycosylation attempts (including ones that worked with the oxygen analogue)\textsuperscript{146} were made, unfortunately with no success. This caused us to re-evaluate our approach.

![Scheme 3.2 Attempt at glycosylating 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-\(\alpha\)-D-glucopyranosyl chloride.](image)

Several glycosylation attempts were made using with 20 as a glycosyl donor. No desired product was isolated from any of these attempts. a) \textit{para}-Methoxyphenol, benzyltriethylammonium chloride, DCM, 1M NaOH, 24 h; b) Sodium \textit{para}-methoxyphenolate, THF, r.t., 24 h; c) \textit{para}-Methoxyphenol, NaOH, acetone, r.t., 24 h.

3.3.2 Synthesis of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-\(\alpha\)-D-glucopyranosyl trichloroacetimidate (22).

After some unsuccessful attempts to obtain our desired product using the chloride donor 20, an alternative route was explored. Upon examination of the
literature, it was found that trichloroacetimidate 5-thiosugar donors had been successfully used when glycosylating various acceptors.\textsuperscript{147-152} Therefore, the α-trichloroacetimidate sugar donor, 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranosyl trichloroacetimidate (22) was prepared with the anticipation that it would prove more useful than the chloride donor 20. The general procedure for the synthesis of 22 is outlined in Scheme 3.3.

Scheme 3.3 Synthesis of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranosyl trichloroacetimidate glycosyl donor (22).

An alternative glycosyl donor was synthesized by introducing a trichloroacetimidate leaving group at the anomeric center.\textsuperscript{148-152} a) Hydrazine acetate, DMF, r.t., 4 h; b) Trichloroacetonitrile, DBU (cat.), DCM, 0°C, 0.5 h.

3.4 Synthesis of a potential substrate for \textit{O}-GlcNAcase.

3.4.1 Glycosylation of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranosyl trichloroacetimidate (22) with para-methoxyphenol under low temperature conditions.

After isolating the trichloroacetimidate donor 22, the next step was glycosylation. It was decided that this would be attempted at low temperature (-78 °C), as several references had successfully made use of various trichloroacetimidate donors under low temperature conditions.\textsuperscript{150,152-154} The first glycosylation conditions that were explored are summarized in Scheme 3.4, and the detailed procedure is outlined at the end of this chapter (see methods section 3.6).
Scheme 3.4 An α-glycoside product is generated under low temperature reaction conditions.

a) para-Methoxyphenol, BF$_3$·OEt$_2$ (cat.), DCM, - 78 °C, 1 h.

3.4.2 Back to the drawing board: an α-glycosylated product will not be useful, O-GlcNAcase only processes β-glycosides.

While it was encouraging to finally obtain a 5-thio glycoside product, it unfortunately and surprisingly did not possess the desired stereochemistry. Glycoside hydrolases are very specific as to which anomer of a sugar substrate they will process.$^{35}$ As mentioned previously, only β-glycosides are processed by O-GlcNAcase.$^{17}$ This makes the α-anomer useless for our purposes. However, all was not lost. This α-glycoside product was a step in the right direction. The obstacle was now how to obtain the β-configured version of this glycoside. Being somewhat puzzled by the stereochemical selectivity of this previous reaction, we consulted the literature for some potential explanations of the observed results. We were relieved to discover that we were not the only ones to have faced this issue of stereoselectivity when using 5-thio sugar glycosyl donors. There were references that revealed that when using various 5-thio sugar donors, α-glycoside products greatly predominated.$^{147,149-151,155-157}$ This is an interesting phenomenon, and while there are currently no concrete explanations for this, it
seems that the endocyclic ring sulphur gives rise to a stronger anomeric effect than that observed for sugars containing an endocyclic ring oxygen.

In one interesting report, exclusive production of the β-anomer was obtained although this necessitated the use of a 2-phthamido group, which was not readily feasible given the synthetic route we used.\textsuperscript{147} Fortunately, there were reaction conditions found in a few references that demonstrated how glycosylation conditions may be manipulated when using 5-thio sugar trichloroacetimidate donors, to achieve reasonable, though not exclusive selectivity for the β-glycoside.\textsuperscript{151,153,157} The main difference contributing to the formation of the β-glycoside was the temperature under which the glycosylation reactions took place. It was found in the literature that by using a Lewis acid promoter, catalytic $\text{BF}_3\cdot\text{OEt}_2$, and a higher temperature (-20 °C → r.t.), the β-anomer was generated to a much greater extent than what we had found when carrying out the reaction at -78 °C.\textsuperscript{151,153,157} Following this promising lead from the literature, glycosylation using 22 was attempted again but using higher temperature conditions (see Scheme 3.5).

3.4.3 The synthesis of para-methoxyphenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-β-D-glucopyranoside.

The reaction conditions used to prepare para-methoxyphenyl 2-acetamido-3,4,6,-tri-O-acetyl-2-deoxy-5-thio-β-D-glucopyranoside (24) are summarized in Scheme 3.5 and a detailed synthetic procedure follows in the methods section 3.6.
Scheme 3.5 An increase in reaction temperature increased the ratio of β- to α-glucosides.

The glycosylation of 22 was achieved with a greater selectivity for the β-anomer than previously observed.\textsuperscript{151,153,157} Ratios were determined using $^1$H NMR spectroscopy of the isolated product mixture. a) \textit{para}-Methoxyphenol, BF$_3$·OEt$_2$ (cat.), DCM, -20 °C → r.t., 1 h.

Once each anomer was isolated, the next step was to remove the acetyl groups. Because each protected anomer was isolated in such a small quantity, it was decided that the deprotection would be performed first on the α-anomer (the less important compound) to identify appropriate reaction conditions. Upon successful deprotection of the α-anomer, deprotection of the β-anomer was carried out. The reaction conditions are summarized below in Scheme 3.6, followed by detailed procedures in the methods section.
Scheme 3.6 Deprotection of pMP-5S-GlcNAc 23 and 24 glycosylated products.
Each deprotected anomer was obtained using standard deprotection procedures. a) NaOMe (cat.), MeOH, r.t., 0.5 h; b) AcOH, MeOH (pH 4).

3.4.4 pMP-5S-GlcNAc (26): isolated!

We were pleased to successfully isolate pMP-5S-GlcNAc (26) with the appropriate stereochemistry at the anomeric center. It is interesting that the temperature was such an important factor for obtaining a reasonable yield of the β-glycoside. This temperature dependence on stereoselectivity has been documented in a few synthetic procedures involving 5-thiosugar donors, as mentioned earlier.\(^{151,153,157}\) It is likely that this selectivity arises from kinetic differences that are apparent when using different reaction temperatures, as a thermodynamic explanation would require that there be reversibility of the glycosylation reaction, which is highly unlikely. A more detailed explanation will require further experimentation including closely monitored kinetic experiments.
Regardless, the isolation of this compound required some careful consideration and willingness to plunge forward toward alternative approaches when other strategies failed.

3.5 pMP-5SGlcNAc (26): a substrate for O-GlcNAcase.

Once pMP-5SGlcNAc (26) was prepared, our laboratory was curious to investigate if this compound could be a substrate for O-GlcNAcase. This question is fundamentally interesting since it could expand our understanding of the catalytic mechanism of O-GlcNAcase, as well as enlighten us as to how tolerant this enzyme is toward variants of its natural substrate. Dr. Tracy Gloster carried out kinetic studies and found that O-GlcNAcase was indeed capable of processing pMP-5SGlcNAc (26), with an enzymatic efficiency ($k_{\text{cat}}/K_m$) of 0.054 μM s$^{-1}$ mg$^{-1}$ mM$^{-1}$, which is only 5-fold less efficient than the processing of pMP-GlcNAc ($k_{\text{cat}}/K_m = 0.27$ μM s$^{-1}$ mg$^{-1}$ mM$^{-1}$), which more closely resembles the natural substrate. This shows that O-GlcNAcase tolerates substitution of the endocyclic ring oxygen with sulphur surprisingly well. This observation is interesting in light of the finding that UDP-5SGlcNAc acts as a poor substrate for OGT and suggests that the cationic character of the transition states differ between these two enzymes. These findings are likely just the early days of studies relating to understanding the processing and use of 5SGlcNAc (18) by OGT and O-GlcNAcase. Nevertheless, these discoveries are significant and a good step forward.
3.6 Methods

3.6.1 Detailed methods for the synthesis 5SGlcNAc

The synthesis of 5SGlcNAc (18) was carried out following the literature procedure established by Tanahashi et al.,\textsuperscript{144} as well as that of Hasegawa et al.\textsuperscript{145} However, the conditions at certain steps were modified in order to obtain improved results. In all cases where the spectral characterization was available for literature compounds, the data was in good agreement. Owing to the absence of full characterization in the literature, data is provided here for each compound for completeness and for future reference.

\textit{2-Acetamido-2-deoxy-3,4:5,6-di-O-isopropylidene-aldehydo-D-glucose dimethyl acetal (10).}\textsuperscript{145} 15.0 g (67.8 mmol) of 9 was suspended in 1,4- dioxane (150 mL) at 80 °C. 2,2-dimethoxypropane (60 mL) was added to the suspension, together with 2.25 g (11.8 mmol) of tosic acid. The reaction was stirred for 24 hours at 80 °C. The mixture was cooled and subsequently treated with enough potassium carbonate to obtain a neutral solution. The reaction mixture was then filtered and concentrated under high vacuum. The concentrated crude reaction mixture was subjected to flash column silica chromatography using a solvent system increasing in polarity from 1 to 2% methanol in chloroform, affording the title compound as a caramel coloured viscous syrup (7.35 g, 57%). $^1$H-NMR (500 MHz, CDCl$_3$) $\delta$ (ppm) 5.94 (d, $J = 10.0$ Hz, 1H), 4.17 (dd, $J = 9.8$, 6.8 Hz, 1H), 4.09 (d, $J = 6.6$ Hz, 1H), 3.95 (d, $J = 8.1$ Hz, 1H), 3.80 (m, 2H), 3.66 (q, $J = 4.4$ Hz, 1H), 3.45 (s, 2H), 3.40 (t, $J = 7.8$ Hz, 1H), 3.16 (s, 3H), 3.10 (s, 3H), 1.79 (s, 3H), 1.23 (s, 2H), 1.16 (s, 2H), 1.13 (s, 3H), 1.10 (s, 3H); $^{13}$C-NMR (125 MHz,
2-Acetamido-2-deoxy-3,4-O-isopropylidene-aldehydo-D-glucose dimethyl acetal (11). 145 10.35 g (29.80 mmol) of 10 was dissolved in a solution of 80% acetic acid in water and stirred at 40 °C for 2 hours. Upon completion of the reaction aliquots of the mixture were concentrated under high vacuum until the whole reaction mixture was concentrated to afford a thick oil. This oil was dried directly under high vacuum until the acetic acid was removed. The crude reaction mixture was then purified via flash column silica chromatography using a solvent system of increasing polarity, beginning at 7% and increasing to 10% methanol in chloroform. The pure fractions were concentrated and dried under high vacuum to afford the title compound as yellow syrup. (8.55 g, 86%). 1H-NMR (500 MHz, CDCl3) δ (ppm) 6.32 (d, J = 9.7 Hz, 1H), 4.42 (d, J = 7.0 Hz, 1H), 4.34 (t, J = 9.7 Hz, 1H), 9.48 (d, J = 9.5 Hz, 1H), 3.73 (dd, J = 11.2, 3.1 Hz, 1H), 3.60 (m, 3H), 3.36 (s, 3H), 3.27 (s, 3H), 2.02 (s, 3H), 1.33 (s, 3H); 13C-NMR (125 MHz, CDCl3) δ (ppm) 171.23, 109.08, 102.64, 78.02, 76.21, 73.45, 64.17, 54.61, 52.48, 50.04, 26.96, 23.19.

2-Acetamido-6-O-benzoyl-2-deoxy-3,4-O-isopropylidene-aldehydo-D-glucose dimethyl acetal (12). 144 To a stirred solution of 11 (7.70 g, 22.2 mmol) in pyridine at -20°C, dry benzoyl chloride (3.14 g, 22.2 mmol) was added. The mixture was stirred for 6 hours while maintaining the temperature between -10 and -5 °C. Upon completion of the reaction the mixture was diluted with chloroform. The crude mixture was washed twice with each of 2 M HCl, saturated
sodium carbonate, and water. Each aqueous layer was back extracted with chloroform. The combined organic layers were dried with magnesium sulphate, filtered, and concentrated in vacuo. The concentrated crude residue was subjected to flash column silica chromatography using a solvent system of increasing polarity starting with 1% and increasing to 2% methanol in chloroform. The pure fractions were concentrated in vacuo, dried with MgSO₄, and then the desired material was crystallized from ethyl acetate and hexanes to afford the title compound as white needles (7.68 g, 87%). ¹H-NMR (500 MHz, CDCl₃) δ (ppm) 8.11 (dd, J = 8.5, 1.3 Hz, 2H), 7.53 (t, J = 7.5 Hz, 1H), 7.41 (t, J = 8.2 Hz, 2H), 4.45 (m, 4H), 4.24 (d, J = 10.1 Hz, 1H), 3.90 (m, 1H), 3.71 (t, J = 8.7 Hz, 1H), 3.36 (s, 3H), 3.26 (s, 3H), 2.03 (s, 3H), 1.35 (s, 3H), 1.35 (s, 3H), 1.32 (s, 3H); ¹³C-NMR (125 MHz, CDCl₃) δ (ppm) 171.20, 166.62, 132.99, 129.82, 128.29, 109.07, 102.16, 79.03, 75.38, 71.62, 66.83, 54.67, 51.95, 50.36, 26.95, 26.93, 23.12.

2-Acetamido-6-O-benzoyl-2-deoxy-3,4-O-isopropylidene-5-O-mesyl-aldehydro-D-glucose dimethyl acetal (13). 6.52 g (16.4 mmol) of 12 was cooled to 0 °C in pyridine (14 mL). To this solution mesyl chloride (2.50 g, 20.8 mmol) was added. The reaction was kept at 0 °C until judged complete by TLC analysis (2 hours). The mixture was then concentrated under high vacuum. The resulting residue was dissolved in chloroform and the solution was successively washed twice with each of 2 M HCl, saturated sodium carbonate solution, and water. Each aqueous layer was back extracted with chloroform. All organic layers were combined, dried with MgSO₄, concentrated in vacuo, and placed under high
vacuum until residual pyridine was removed. The crude reaction mixture was purified via flash column silica chromatography using a solvent system of increasing polarity from 1% to 2% methanol in chloroform. Pure fractions were concentrated in vacuo and dried under high vacuum, giving rise to the pure product as an amorphous white solid (7.64 g, 98%). $^1$H-NMR (500 MHz, CDCl$_3$) $\delta$ (ppm) 8.12 (d, $J = 7.1$ Hz, 1H), 7.60 (t, $J = 7.4$ Hz, 1H), 7.48 (t, $J = 8.1$ Hz, 2H), 5.84 (d, $J = 9.7$ Hz, 1H), 5.14 (m, 1H), 4.80 (dd, $J = 12.5$, 2.6 Hz, 1H), 4.49 (dd, $J = 12.5$, 7.1 Hz, 1H), 4.45 (m, 2H), 4.39 (m, 1H), 4.00 (dd, $J = 7.9$, 6.2 Hz, 1H), 3.45 (s, 3H), 3.34 (s, 3H), 3.16 (s, 3H), 2.07 (s, 3H), 1.78 (s, 3H), 1.45 (s, 3H), 1.43 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) $\delta$ (ppm) 170.07, 166.10, 133.29, 129.91, 128.48, 110.39, 103.18, 78.40, 75.65, 63.55, 55.78, 52.79, 49.69, 38.89, 26.99, 26.90, 23.36.

**2-Acetamido-5,6-anhydro-2-deoxy-3,4-O-isopropylidene-aldehydo-L-idose dimethyl acetal (14).**$^{144}$ To a solution of 13 (6.23 g, 13.1 mmol) in dry chloroform (62 mL) at -20 °C was added drop-wise a fresh solution of sodium methoxide (0.50 g Na in 20 mL of methanol). The temperature of the reaction mixture was maintained between -10 °C and 0 °C until the reaction was judged complete by TLC analysis (5 hours). Upon completion of the reaction, additional methanol (102 mL) was added to the mixture. The reaction mixture was treated with H$^+$ amberlite ion exchange resin (IR-120) until the reaction mixture reached a pH of 7. In a small number of cases, if the pH of the solution became acidic, enough K$_2$CO$_3$ was added to increase the pH back to 7. The resin was filtered and washed with additional methanol. The filtrate was concentrated in vacuo and the
resulting residue triturated with ether and hexanes to afford a white amorphous solid (3.51 g, 92%). $^1$H-NMR (500 MHz, CDCl$_3$) δ (ppm) 5.91 (d, $J = 9.8$ Hz, 1H), 4.37 (d, $J = 7.1$ Hz, 1H), 4.18 (m, 2H), 3.36 (s, 3H), 3.35 (m, 1H), 3.25 (s, 3H), 2.98 (m, 1H), 2.80 (m, 1H), 2.75 (dd, $J = 5.1$, 4.2 Hz, 1H), 1.97 (s, 3H), 1.35 (s, 3H), 1.32 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 170.03, 109.79, 102.72, 78.36, 76.00, 55.43, 52.20, 50.92, 48.67, 43.75, 26.88, 26.76, 23.17.

2-Acetamido-2,5,6-trideoxy-5,6-epithio-3,4-O-isopropylidine-aldehydo-D-glucose dimethyl acetal (15).$^{144}$ To a solution of 14 (3.65 g, 12.6 mmol) in dry methanol (78 mL) was added thiourea (2.88 g, 37.9 mmol) after which the mixture was stirred at 60 °C for 2 h Upon completion of the reaction, the mixture was cooled to room temperature and then concentrated in vacuo. The title compound was purified using flash column silica chromatography using a solvent system of 2% methanol in chloroform (3.77 g, 98%). $^1$H-NMR (500 MHz, CDCl$_3$) δ (ppm) 5.85 (d, $J = 9.4$ Hz, 1H), 4.33 (m, 3H), 3.40 (s, 3H), 3.36 (s, 3H), 3.26 (t, $J = 7.9$ Hz, 1H), 2.92 (m, 1H), 2.51 (d, $J = 6.0$ Hz, 1H), 2.26 (d, $J = 5.2$ Hz, 1H), 1.99 (s, 3H), 1.44 (s, 3H), 1.39 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) δ (ppm) 169.67, 109.95, 103.38, 81.91, 78.22, 55.38, 53.56, 49.39, 33.92, 27.04, 27.03, 22.96.

2-Acetamido-6-O-acetyl-5-S-acetyl-2-deoxy-3,4-O-isopropylidine-5-thio-aldehydo-D-glucose dimethyl acetal (16).$^{144}$ A solution of 15 (1.02 g, 3.34 mmol), acetic anhydride (31 mL), potassium acetate (1.53 g, 15.6 mmol), and acetic acid (5 mL) was brought to reflux at 160 °C with stirring for 20 hours. After completion of the reaction, the mixture was cooled to room temperature and
concentrated under high vacuum. The remaining residue was extracted with chloroform and successively washed with 2 M HCl, saturated sodium bicarbonate, and brine. Each aqueous layer was back extracted with chloroform. The pooled organic layers were dried with MgSO₄, and evaporated under vacuum to afford a dark syrup. Flash column silica chromatography using a solvent system of 30% hexanes in ethyl acetate furnished the title compound as a white crystalline solid (0.980 g, 72%). ¹H-NMR (500 MHz, CDCl₃) δ (ppm) 5.83 (d, J = 9.7 Hz, 1H), 4.37 (m, 2H), 4.32 (d, J = 6.8 Hz, 1H), 4.26 (dd, J = 11.5, 5.1 Hz, 1H), 4.16 (d, J = 7.5 Hz, 1H), 3.96 (m, 1H), 3.82 (t, J = 7.9 Hz, 1H), 3.37 (s, 3H), 3.30 (s, 3H), 2.36 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 1.42 (s, 3H), 1.39 (s, 3H); ¹³C-NMR (125 MHz, CDCl₃) δ (ppm) 191.92, 168.67, 167.93, 107.89, 101.17, 75.71, 74.70, 61.90, 53.50, 50.68, 48.37, 43.03, 28.58, 25.13, 24.90, 21.38, 18.77.

2-Acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-5-thio-α-D-glucopyranose (17). In a solution of 10:1 acetic acid:2 M HCl (77 mL) 16 (2.57 g, 6.31 mmol) was dissolved and the mixture was warmed to 40 °C for 24 hours under an atmosphere of nitrogen. The reaction mixture turned a bright pink colour. Upon completion of the reaction, the mixture was concentrated without heating under high vacuum. The resulting dark brown residue was dried thoroughly under high vacuum until residual acetic acid was removed and a dark brown syrup was obtained. The syrup was dissolved in acetic anhydride (13 mL) and pyridine (51 mL) and stirred overnight at 0°C. Upon completion of the reaction, the mixture was concentrated under high vacuum without heating. The resulting syrup was
subjected to flash column silica chromatography using a solvent system increasing in polarity 2 to 3% methanol in chloroform to give the title compound as an off-white solid that crystallized from ethyl acetate and hexanes to give pure white needles of the title compound (1.74 g, 68% over two steps). $^1$H-NMR (500 MHz, CDCl$_3$) $\delta$ (ppm) 5.92 (d, $J = 3.0$ Hz, 1H), 5.70 (d, $J = 8.9$ Hz, 1H), 5.37 (dd, $J = 10.7$, 9.6 Hz, 1H), 5.16 (dd, $J = 10.9$, 9.7 Hz, 1H), 4.63 (m, 1H), 4.34 (dd, $J = 12.1$, 5.0 Hz, 1H), 4.03 (dd, $J = 12.1$, 3.2 Hz, 1H), 3.50 (m, 1H), 2.17 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 1.90 (s, 3H), 1.60 (s, 3H); $^{13}$C-NMR (125 MHz, CDCl$_3$) $\delta$ (ppm) 171.73, 170.60, 169.52, 169.16, 168.77, 72.79, 71.78, 71.47, 61.10, 55.20, 39.75, 23.08, 21.14, 20.65, 20.53.

**2-Acetamido-2-deoxy-5-thio-α-D-glucopyranose (18).** In a solution of methanol (1.9 mL), 0.050 g (0.12 mmol) of 17 was dissolved and a catalytic amount of sodium methoxide (enough to raise the pH of the reaction solution to between 9 and 10) was added. The reaction was followed closely by TLC and was found to be complete after 1 hour at room temperature. The solution was then neutralized by the drop-wise addition of a dilute solution of acetic acid in methanol (pH 4) until the pH was adjusted to 7. The reaction mixture was concentrated without heating under high vacuum. The final product was isolated as a white solid by flash silica column chromatography using a solvent system of 12:2:1 ethyl acetate:methanol:water (0.017 g, 58%). $^1$H-NMR (600 MHz, MeOH, $d_4$) $\delta$ (ppm) 4.89 (d, $J = 3.2$ Hz, 1H), 4.12 (dd, $J = 10.5$, 2.8 Hz, 1H), 3.88 (m, 2H), 3.70 (dd, $J = 10.5$, 8.82 Hz, 1H), 3.60 (dd, $J = 10.5$, 8.8 Hz, 1H), 3.60 (dd, $J =$
10.4, 9.0 Hz, 1H), 3.28 (m, 1H), 2.00 (s, 3H); $^{13}$C-NMR (150 MHz, MeOH, d$_4$) δ (ppm) 171.91, 75.43, 72.07, 72.05, 61.20, 58.56, 43.44, 21.27.

3.6.2 Detailed synthetic methods for the synthesis of pMP-5SGlcNAc (26).

2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranosyl chloride (20). A procedure analogous to that for generating 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosyl chloride was used here.$^{146}$ 17 (0.025 g, 0.062 mmol) was dissolved in acetyl chloride (0.5 mL) and cooled to 0 °C. HCl gas was bubbled into the cooled solution. Once the mixture was saturated with HCl gas, the mixture was capped and allowed to stir at room temperature for 72 hours. Upon completion of the reaction, the mixture was diluted with dichloromethane and cooled by directly adding ice to the solution. The cooled mixture was washed two times with saturated sodium bicarbonate, water, and brine. Each aqueous layer was back extracted with dichloromethane. The organic layers were pooled, dried with MgSO$_4$, and concentrated in vacuo. The reaction gave rise to a bright yellow oil (0.016 g, 73%). $^1$H-NMR (600 MHz, CDCl$_3$) δ (ppm) 5.98 (d, J = 8.4 Hz, 1H), 5.31 (m, 2H), 5.21 (m, 1H), 4.58 (m, 1H), 4.36 (dd, J = 12.2, 5.0 Hz, 1H), 4.05 (dd, J = 12.2, 3.0 Hz, 1H), 3.61 (m, 1H), 2.01 (s, 3H), 1.99 (s, 3H), 1.98 (s, 3H), 1.91 (s, 3H); $^{13}$C-NMR (150 MHz, CDCl$_3$) δ (ppm) 171.52, 170.53, 169.84, 169.22, 71.40, 71.25, 64.95, 60.76, 57.42, 40.52, 23.13, 20.61, 20.52; HRMS (m/z): [M+H]$^+$ calcd for C$_{14}$H$_{20}$ClNO$_7$S: 382.0727; found 382.0726.

2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranose (21).

Anomeric deacetylation was effected in a manner similar to that reported previously for different saccharides.$^{151,153,157}$ To a solution of 17 (0.200 g, 0.490
mmol) in DMF (1 mL) at room temperature, was added hydrazine acetate (0.050 g, 0.54 mmol). The mixture was left to stir until all starting material was consumed (6 hours) as judged by TLC. The mixture was then concentrated under high vacuum, and co-evaporated twice with toluene, without heating. The resulting residue was taken up in ethyl acetate and washed two times with saturated sodium bicarbonate, water (until a neutral pH was obtained), and brine. Each aqueous layer was back extracted with ethyl acetate. The pooled organic layers were dried using MgSO₄, filtered, and concentrated in vacuo. The residue was subjected to flash column silica chromatography using a solvent system of 30% hexanes in ethyl acetate, and subsequently concentrated under high vacuum to afford the title compound as a white solid. Crystallization from ethyl acetate and hexanes afforded a white powder (0.144 g, 80%). ¹H-NMR (600 MHz, CDCl₃) δ (ppm) 4.89 (dd, J = 10.5, 2.8 Hz, 1H), 3.88 (m, 2H), 3.70 (dd, J = 10.5, 8.8 Hz, 1H), 3.60 (dd, J = 10.4, 8.9 Hz, 1H), 3.28 (m, 1H), 2.00 (s, 3H); ¹³C-NMR (150 MHz, CDCl₃) δ (ppm) 171.91, 75.43, 72.07, 72.05, 61.20, 58.56, 43.44, 21.27. HRMS (m/z): [M+H]⁺ calcd for C₁₄H₂₁NO₈S: 364.1066; found 364.1070.

2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-α-D-glucopyranosyl trichloroacetimidate (22). Preparation of the trichloroacetimidate donor was carried out by modification of a previously described procedure used for different saccharides.¹⁵⁷ 21 was dissolved in dichloromethane at 0 °C, and to this solution was added trichloroacetonitrile (0.181 g, 1.27 mmol) and a catalytic amount of DBU (~1 drop). The reaction was allowed to stir at 0 °C until completion (0.5
hours). The mixture was then diluted with benzene and concentrated under high vacuum. The crude residue was subjected to flash column silica chromatography using a solvent system of 40% hexanes in ethyl acetate. The desired material was isolated as a clear oil, which upon standing, solidified to give a white solid (0.086 g, 76%).

\[ ^1H-NMR \ (600 \text{ MHz, } \text{CDCl}_3) \ \delta \ (\text{ppm}) \ 8.77 \ (s, \ 1H), \ 6.08 \ (d, \ J = 3.0 \ Hz, \ 1H), \ 5.79 \ (d, \ J = 8.8 \ Hz, \ 1H), \ 5.37 \ (dd, \ J = 10.7, \ 9.8 \ Hz, \ 1H), \ 5.20 \ (dd, \ J = 10.7, \ 9.8 \ Hz, \ 1H), \ 4.65 \ (m, \ 1H), \ 4.29 \ (dd, \ J = 12.1, \ 5.0 \ Hz, \ 1H), \ 4.00 \ (dd, \ J = 12.1, \ 3.1 \ Hz, \ 1H), \ 3.49 \ (m, \ 1H), \ 2.00 \ (s, \ 3H), \ 1.99 \ (s, \ 3H), \ 1.98 \ (s, \ 3H); \ ^{13}C-NMR \ (150 \text{ MHz, } \text{CDCl}_3) \ \delta \ (\text{ppm}) \ 171.51, \ 170.49, \ 169.59, \ 169.21, \ 159.20, \ 90.79, \ 77.82, \ 71.69, \ 71.31, \ 60.99, \ 55.80, \ 40.14, \ 23.06, \ 20.63, \ 20.60, \ 20.52. \]

HRMS (m/z): [M+H]+ calcd for C_{16}H_{121}N_{2}O_{8}S\text{Cl}_{3}: \ 507.0162; \ \text{found} \ 507.0173.

**para-Methoxyphenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-5-thio-β-D-glucopyranoside (24).** Glycosylation was effected by adaptation of a reported method used for glycosylation of trichloroacetimidate donors of other saccharides \(^{149,153,157}\). A solution of 22 (0.050 g, 0.100 mmol) and \(p\)-methoxyphenol (0.025 g, 0.20 mmol) in dichloromethane (0.77 mL) was stirred at -20 °C. To this solution a catalytic amount of BF\(_3\)-OEt\(_2\) (~ 1 drop) was added, and the reaction was immediately allowed to warm to room temperature. The reaction was stirred for 1 hour, after which time the reaction was judged complete by TLC. Two equivalents of triethylamine (0.026 mL) were then added to the reaction mixture. The mixture was concentrated under high vacuum without heating. Flash column silica chromatography was carried out to isolate the products and the \(^1H\) NMR spectrum revealed a mixture of two products; the \(α\)- and \(β\)-anomers in a ratio of
70% $\alpha$ and 30% $\beta$. The two anomers were separated via flash column silica chromatography using a solvent system 40% hexanes in ethyl acetate to afford the pure $\beta$-glycoside (0.056 g, 12%) and $\alpha$-glycoside (0.096 g, 21%). Data provided for the $\beta$-glycoside: $^1$H-NMR (600 MHz, CDCl$_3$) $\delta$ (ppm) 6.89 (d, $J = 9.1$ Hz, 2H), 6.77 (d, $J = 9.1$ Hz, 2H), 5.88 (d, $J = 8.8$ Hz, 1H), 5.31 (m, 1H), 5.13 (d, $J = 6.3$ Hz, 1H), 5.04 (m, 1H), 4.52 (m, 1H), 4.28 (m, 2H), 3.70 (s, 3H), 3.14 (m, 1H), 2.02 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H), 1.92 (s, 3H); $^{13}$C-NMR (150 MHz, CDCl$_3$) $\delta$ (ppm) 170.55, 170.15, 169.70, 168.95, 155.44, 150.46, 118.20, 114.71, 80.57, 71.04, 69.16, 63.44, 55.67, 46.00, 29.72, 23.41, 20.81, 20.72, 20.70. HRMS (m/z): [M+H]$^+$ calcd for C$_{21}$H$_{27}$N$_2$O$_9$S: 470.1485; found 470.1478.

**para-Methoxyphenyl 2-acetamido-2-deoxy-5-thio-$\beta$-D-glucopyranoside (26).**

To a solution of 24 (0.0062 g, 0.013 mmol) in methanol (0.25 mL) was added a catalytic amount of sodium methoxide (enough to bring the reaction solution to pH 10). The reaction was allowed to stir at room temperature. After twenty minutes a white solid began to precipitate out of solution. The reaction was complete after 30 minutes as judged by TLC. The reaction was then diluted with additional methanol (5 mL) and subsequently brought to a neutral pH value by the drop-wise addition of a dilute mixture of acetic acid in methanol (pH 4). The mixture was concentrated under high vacuum without heating. The title compound was isolated by precipitation from ethanol and ether as a fine white powder (0.0033 g, 66%). $^1$H-NMR (600 MHz, MeOH, D$_4$) $\delta$ (ppm) 6.99 (d, $J = 9.2$ Hz, 2H), 6.83 (d, $J = 9.2$ Hz, 2H), 5.10 (d, $J = 9.3$ Hz, 1H), 4.19 (dd, $J = 9.6$ Hz, 1H), 3.96 (dd, $J = 11.4$, 3.7 Hz, 1H), 3.79 (dd, $J = 11.4$, 6.5 Hz, 1H), 3.74 (s, 3H),
3.60 (dd, $J = 10.1$ Hz, 1H), 3.38 (dd, $J = 9.9$ Hz, 1H), 2.89 (m, 1H), 1.96 (s, 3H);

$^{13}$C-NMR (150 MHz, D$_2$O) $\delta$ (ppm) 172.44, 155.27, 151.78, 117.50, 114.14, 80.79, 75.08, 74.32, 61.23, 59.86, 54.64, 46.08, 21.58. HRMS ($m$/z): [M+H]$^+$
calcd for C$_{15}$H$_{21}$NO$_6$S: 344.1168; found 344.1157.
CHAPTER 4: CONCLUSIONS AND FUTURE WORK

4.1 Conclusions

The goal for synthesizing the compounds described in this thesis was to gain a greater understanding of the role of O-GlcNAc and its significance in the cell. One way of addressing questions relating to the significance of O-GlcNAc is through the design of cell permeable, potent, and selective inhibitors. By introducing such inhibitors into cells we have the opportunity to manipulate the levels of O-GlcNAc and evaluate the effects. In order to accomplish this goal however, it was first necessary to reflect on the active site of the enzymes and on previous inhibitors already synthesized for O-GlcNAcase and OGT, both in terms of their successes and shortcomings. A crucial requirement in furthering the understanding of this enzyme was the development of inhibitors that had a more acute potency and selectivity than inhibitors already developed.\(^{40}\)

Studies presented in the first part of this thesis introduce a second generation of O-GlcNAcase inhibitors, many of which improved upon both the binding affinity and selectivity of previous inhibitors developed by colleagues Whitworth and Macauley and coworkers.\(^{40}\) Several potent, nanomolar affinity inhibitors were created. A key discovery that accounts for much of the improvements made in some of these second generation inhibitors was the introduction of an electron rich amino moiety at the 2'-position the thiazoline ring. By introducing this group we were able to increase the probability of the
endocyclic nitrogen of the thiazoline ring being protonated at physiological pH. The positive charge generated through protonation of the endocyclic nitrogen of such inhibitors was able to provide the predicted ionic interaction with a key catalytic aspartate residue within the active site of O-GlcNAcase.\textsuperscript{107}

It was also found that maintaining some steric bulk attached to the 2'-position of the thiazoline ring on the inhibitors was important for selectivity for human O-GlcNAcase over the functionally related human lysosomal \(\beta\)-hexosaminidases. This was first noted during the development of the first generation of inhibitors\textsuperscript{40}. O-GlcNAcase is well known to possess a considerably deeper binding pocket that can accommodate greater steric bulk\textsuperscript{129} compared to the relatively shallow binding pocket of the hexosaminidase enzymes.\textsuperscript{158} Therefore, despite there being several inhibitors that were created with low nanomolar binding to O-GlcNAcase, it was the inhibitor Thiamet-G, which possesses a 2'-aminoethyl group, that gained most attention in our laboratory. It has a \(K_i\) value of 22 nM while maintaining an impressive 37,000 fold selectivity for O-GlcNAcase over functionally related lysosomal \(\beta\)-hexosaminidase enzymes.\textsuperscript{107}

Due to Thiamet-G’s potency and selectivity, it was evaluated in several cellular studies relating to the reciprocal relationship observed between the O-GlcNAc modification and phosphorylation of the cellular protein tau.\textsuperscript{107} This reciprocal relationship has been of special interest to our laboratory as there have been several studies documenting the correlation between the hyper-phosphorylated state of the cellular protein tau and the development and
incidence of Alzheimer’s disease. One hypothesis developed in the Vocadlo laboratory is that by increasing levels of the O-GlcNAc modification of tau, the levels of phosphorylation may be decreased. Promising results observed by the group have prompted evaluating the long-term effects of treating animals with Thiamet-G, with the hope that it may serve to validate a potential therapeutic strategy to tau hyperphosphorylation.

The second part of this thesis involved synthesis of 5S-GlcNAc. This compound was originally sought out for its potential to serve as a probe of O-GlcNAcase. Upon treating cells with 5S-GlcNAc, however, it was found that the O-GlcNAc modification on proteins decreased. This observation led to the hypothesis that UDP-5S-GlcNAc may act as an inhibitor of OGT. This was an exciting prospect, as there were no previous reports of a cell permeable inhibitor of OGT. UDP-5S-GlcNAc was chemoenzymatically synthesized by Wesley Zandberg and was found through kinetic studies performed by David Shen that it does act as an inhibitor of OGT, with a $K_i$ value of 8 μM. Although this inhibitor has a moderate binding affinity, it is the first cell permeable inhibitor of OGT, and will most likely be modified in the future to create new inhibitors, hopefully with improved binding affinity. This inhibitor, as well as future variants, may act as useful research tools.

Derivatives of 5S-GlcNAc were also prepared including one bearing a para-methoxyphenyl leaving group. This allowed us to conduct kinetic tests with this putative substrate and it was found that O-GlcNAcase was capable of
efficiently processing this substrate. Undoubtedly, these findings are only the beginning of further investigations for these two related enzymes.

### 4.2 Future Work

Regardless of what is accomplished in science, there is always more work to be done! Often one discovery simply opens up a new set of questions, and the requirement for more experiments to address them all! The accomplishments presented in this thesis are no exception to this observation. Many studies could be done to further our understanding and knowledge in the areas discussed throughout this body of work.

In chapter 2 the focus was on the development of a potent and selective inhibitor for O-GlcNAcase. Despite our success in developing Thiamet-G, there is still potential for creating new, equally effective or even better inhibitors for this enzyme. This possibility is worth exploring, particularly in light of the potential O-GlcNAcase inhibition has as a therapeutic strategy. If Thiamet-G does prove to be effective in treating Alzheimer disease, then relying completely on this one compound would be unwise. One never knows at what stage in drug development something can go awry, and having alternative compounds one can turn to is important.

It would be interesting if a series of inhibitors for O-GlcNAcase could be designed that do not contain a carbohydrate moiety. It may also be possible to design a set of compounds that have comparable steric bulk to previous inhibitors, while introducing new electronic properties that would produce favorable binding interactions with key residues in the active site of O-
GlcNAcase. Another possibility for future O-GlcNAcase inhibitors would be maintaining the thiazoline ring moiety, as well as the attached 2'-aminoethyl group seen in Thiamet-G, while changing some of the portions of the carbohydrate ring. Introducing heteroatoms within the pyranose ring or as alternatives to the hydroxyl groups attached to the sugar may produce interesting new binding interactions.

In light of the discovery that UDP-5SGlcNAc acts as an inhibitor of OGT, it would be worth investigating the binding capabilities of variants of this scaffold. Introducing other heteroatoms within the carbohydrate portion of UDP-5SGlcNAc may also provide an effective scaffold for an OGT inhibitor. Investigating the inhibitory capabilities of other variants of 5-thiosugars may also be interesting. For example, it would be worth investigating the effects of 5-thio mannose, 5-thiofucose, 5-thioxylose, among others, on inhibition of other targets in vitro. Looking at whether these other compounds have inhibitory capabilities in cells would also be worth investigating.

Discovering that pMP-5SGlcNAc can act as a substrate for O-GlcNAcase makes it worth looking at analogues of this compound. This could be accomplished by making a small library of putative O-GlcNAcase substrates containing the 5SGlcNAc core bearing various leaving groups. It would be interesting to see how different leaving groups affect the rate of turnover by this enzyme. Are larger leaving groups advantageous for O-GlcNAcase processing? Are leaving groups with electron withdrawing or electron donating moieties advantageous for O-GlcNAcase processing? If so, to what extent? These are a
sampling of some of the questions that could be investigated in further studies. These experiments would be valuable, as they would provide information as to which aspects of the substrate are important for successful turnover by O-GlcNAcase and could broaden our understanding of this interesting enzyme.
APPENDIX

Dixon plots were used to determine $K_i$ values of the inhibitors presented in chapter 2. Dixon plots were generated by plotting $1/V$ as a function of inhibitor concentration. Rates of substrate processing ($V$) were plotted as the absorbance values of pNP released from pNP-GlcNAc (400 nm) or fluorescence of 4-methylumbelliferone (excitation: 368 nm, emission 450 nm) released from 4-methylumbelliferyl 2-acetamido-2-deoxy-β-D-glucopyranoside by O-GlcNAcase as a function of time. The resulting data was fitted by linear regression. Using this regression, the line can be extrapolated as described below. By plotting the horizontal line that defines $1/V_{\text{max}}$ perpendicular to the y-axis we can determine the intersection with the linear regression, which is the $-K_i$ value for the particular inhibitor of interest.

**Appendix Figure 1** Reciprocal inhibition plot for compound 8d. Rates of substrate processing at several inhibition concentrations were recorded. The reciprocal value of each of these rates were calculated and plotted as a function of inhibition concentration. To calculate our $K_i$ value, `x` was solved for according to its representation of $-K_i$, when $y = 1/V_{\text{max}}$. 
REFERENCES


